

FORM PTO-1300
(REV. 12-2001)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

5/1266

U.S. APPLICATION NO. (if known, see 37 CFR 1.5

to be assigned **10/049196**

INTERNATIONAL APPLICATION NO.

PCT/EP 00/07457

INTERNATIONAL FILING DATE

02 August 2000

PRIORITY DATE CLAIMED

07 August 1999

TITLE OF INVENTION

CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS

APPLICANT(S) FOR DO/EO/US

Uwe Ries; Henning Priepke; Armin Heckel; Herbert Nar; Wolfgang Wienen and Jean Marie Stassen

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A **FIRST** preliminary amendment.
14. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:
Initial Information Data Sheet
Certified Copies of Priority Documents numbered: 199 37 494.5 and 100 25 663.5
Copies of Documents cited in Form 1449A/B PTO

U.S. APPLICATION NO. <u>10/061331 96</u> 10/06 assigned		INTERNATIONAL APPLICATION NO. PCT/EP 00/07457		ATTORNEY'S DOCKET NUMBER 5/1266	
--	--	--	--	------------------------------------	--

21 <input checked="" type="checkbox"/> The following fees are submitted: BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO. \$1040.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$890.00 International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00 International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfy provisions of PCT Article 33(1)-(4) \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT =	CALCULATIONS PTO USE ONLY <table border="1" style="width:100%; border-collapse: collapse;"> <tr> <td style="width:50%;"></td> <td style="width:50%; text-align: right;">\$ 890.00</td> </tr> <tr> <td></td> <td style="text-align: right;">\$ 130.00</td> </tr> </table>			\$ 890.00		\$ 130.00																					
	\$ 890.00																										
	\$ 130.00																										
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).																											
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:15%;">CLAIMS</th> <th style="width:15%;">NUMBER FILED</th> <th style="width:15%;">NUMBER EXTRA</th> <th style="width:15%;">RATE</th> <th style="width:40%;">\$</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>12 - 20 =</td> <td>0</td> <td>x \$18.00</td> <td>\$ 0.00</td> </tr> <tr> <td>Independent claims</td> <td>1 - 3 =</td> <td>0</td> <td>x \$84.00</td> <td>\$ 0.00</td> </tr> <tr> <td colspan="4">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$280.00 \$ 0.00</td> </tr> <tr> <td colspan="4">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$ 1,020.00</td> </tr> </tbody> </table>			CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$	Total claims	12 - 20 =	0	x \$18.00	\$ 0.00	Independent claims	1 - 3 =	0	x \$84.00	\$ 0.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$280.00 \$ 0.00	TOTAL OF ABOVE CALCULATIONS =				\$ 1,020.00
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$																							
Total claims	12 - 20 =	0	x \$18.00	\$ 0.00																							
Independent claims	1 - 3 =	0	x \$84.00	\$ 0.00																							
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				+ \$280.00 \$ 0.00																							
TOTAL OF ABOVE CALCULATIONS =				\$ 1,020.00																							
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.																											
SUBTOTAL =																											
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).																											
TOTAL NATIONAL FEE =																											
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +																											
TOTAL FEES ENCLOSED =																											
		Amount to be refunded: \$																									
		charged: \$																									

a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 02-2955 in the amount of \$ 1,020.00 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 02-2955. A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO: Robert P. Raymond Boehringer Ingelheim Corporation 900 Ridgebury Road, P. O. Box 368 Ridgefield, CT 06877-0368 Date Mailed: February 6, 2002 Express Mail Airbill No. EV 060 417 006 US	 SIGNATURE David A. Dow NAME 46,124 REGISTRATION NUMBER
---	--

INITIAL INFORMATION DATA SHEET

Inventor Information:

Inventor One:

Given Name:	Uwe
Family Name:	Ries
Postal Address Line One:	Tannenstrasse 31
City:	Biberach
State or Province:	Germany
Postal or Zip Code:	88400
Citizenship Country:	DE

Inventor Two:

Given Name:	Henning
Family Name:	Priepke
Postal Address Line One:	Birkenharder Strasse 11
City:	Warthausen
State or Province:	Germany
Postal or Zip Code:	88447
Citizenship Country:	DE

Inventor Three:

Given Name:	Armin
Family Name:	Heckel
Postal Address Line One:	Geschwister-Scholl-Strasse 71
City:	Biberach
State or Province:	Germany
Postal or Zip Code:	88400
Citizenship Country:	DE

Inventor Four:

Given Name:	Herbert
Family Name:	Nar
Postal Address Line One:	Ulrika-Nisch-Strasse 8
City:	Mittelbiberach
State or Province:	Germany
Postal or Zip Code:	88441
Citizenship Country:	DE

Inventor Five:

Given Name:	Wolfgang
Family Name:	Wienen
Postal Address Line One:	Kirschenweg 27
City:	Biberach
State or Province:	Germany
Postal or Zip Code:	88400
Citizenship Country:	DE

Inventor Six:

Given Name:	Jean Marie
Family Name:	Stassen
Postal Address Line One:	Joseph Ravoetstrasse 5
City:	Leuven
State or Province:	Belgin
Postal or Zip Code:	3012
Citizenship Country:	BE

Correspondence Information:**Customer Number or Barcode Label:**

28501

PATENT TRADEMARK OFFICE

Application Information:

Title Line One:	CARBOXYLIC ACID AMIDES,
Title Line Two:	THE PREPARATION THEREOF AND
Title Line Three:	THEIR USE AS PHARMACEUTICAL
Title Line Four:	COMPOSITIONS
Total Drawing Sheets:	0
Formal Drawings?:	N/A
Application Type:	Utility
Docket No.:	5/1266

Continuity Information:

This application is a: 371 of
>Application One: PCT/EP 00/07457
Filing Date: August 2, 2000

Prior Foreign Applications:

Foreign Application One: 199 37 494.5
Filing Date: August 7, 1999
Country: Germany
Priority Claimed: Yes

Foreign Application Two: 100 25 663.5
Filing Date: May 24, 2000
Country: Germany
Priority Claimed: Yes

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Uwe Ries et al) Docket No.: 5/1266
 U.S. Serial No. : to be assigned) Art Unit: to be assigned
 I.A. No. : PCT/EP 00/07457) Examiner: to be assigned
 Confirmation No.: to be assigned)
 I.A. Filing Date : August 2, 2000)
 Submitted : February 6, 2002)
 For : CARBOXYLIC ACID AMIDES, THE PREPARATION
 THEREOF AND THEIR USE AS PHARMACEUTICAL
 COMPOSITIONS

Box PCT
 Assistant Commissioner for Patents
 Washington, D.C. 20231

PRELIMINARY AMENDMENT


Sir:

Prior to examination please amend the above-identified application as follows:

IN THE CLAIMS:

CLEAN COPY OF THE AMENDED CLAIMS

1. (Amended) A carboxylic acid amide compound of the following formula



wherein

one of the groups m or n denotes the number 0 and

the other group m or n denotes the number 1,

Ar denotes a phenylene or naphthylene group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl, hydroxy, C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, said

phenylene group optionally substituted by a second fluorine, chlorine or bromine atom or by a second C₁₋₃-alkyl group,

a thienylene, thiazolyene, pyridinyne, pyrimidinyne, pyrazinyne or pyridazinyne group optionally substituted in the carbon skeleton by a C₁₋₃-alkyl group,

R₁ denotes a C₁₋₃-alkyl group optionally substituted by an amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, phenyl, naphthyl, heteroaryl or 4- to 7-membered cycloalkyleneimino group,

a C₃₋₇-cycloalkyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an amino, C₁₋₅-alkylamino, C₅₋₇-cycloalkylamino or phenyl-C₁₋₃-alkylamino group which may in each case be substituted at the amino-nitrogen atom by a benzoyl or phenylsulphonyl group or by a C₁₋₃-alkyl or C₁₋₃-alkylcarbonyl group optionally substituted in the C₁₋₃-alkyl moiety by a carboxy group,

a 4- to 7-membered cycloalkyleneiminocarbonyl or cycloalkyleneiminosulphonyl group optionally substituted by a C₁₋₃-alkyl group,

an aminosulphonyl group optionally substituted by one or two C₁₋₃-alkyl groups, a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, heteroaryloxy or heteroaryloxy-C₁₋₃-alkoxy group wherein the alkoxy moiety may be substituted in the 2 or 3 position in each case by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a C₃₋₇-cycloalkoxy group, wherein the methylene group in the 3 or 4 position in a C₅₋₇-cycloalkoxy group may be replaced by an -NH group, and said -NH group may be optionally substituted

by a C₁₋₃-alkyl group which may be substituted in the 2 or 3 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, by a C₁₋₃-alkylcarbonyl, arylcarbonyl or arylsulphonyl group or

by an aminocarbonyl, C₁₋₃-alkylaminocarbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group, wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, hydroxy or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group optionally substituted by a carboxy group and

R₅ denotes a cyano group or an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, said heteroaryl groups consisting of a 5-membered heteroaryl group optionally substituted by a C₁₋₃-alkyl group which contains in the heteroaromatic moiety,

an imino group optionally substituted by a C₁₋₃-alkyl group, or an oxygen or sulphur atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen, sulphur or nitrogen atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and two nitrogen atoms or

an oxygen or sulphur atom and two nitrogen atoms,

or a 6-membered heteroarylene group optionally substituted by a C₁₋₃-alkyl group which contains one or two nitrogen atoms in the heteroaromatic moiety,

an isomer or salt thereof.

2. (amended) The compound of formula I according to claim 1 wherein

one of the groups m or n denotes the number 0 and
the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a methyl, hydroxy, methoxy or benzyloxy group, which may be substituted by another methyl group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a methyl group substituted by a dimethylamino, pyrrolidino or imidazolyl group, wherein the imidazolyl moiety may be substituted by a methyl group,

an amino, C₁₋₅-alkylamino, cyclopentylamino or benzylamino group which may be substituted at the amino-nitrogen atom by a carboxy-C₁₋₂-alkyl, C₁₋₃-alkoxycarbonyl-C₁₋₂-alkyl, carboxy-C₁₋₂-alkylcarbonyl or C₁₋₃-alkoxycarbonyl-C₁₋₂-alkylcarbonyl group,

a benzoylamino or phenylsulphonylamino group,

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl, pyrrolidin Sulphonyl or piperidin Sulphonyl group,

a C₁₋₃-alkoxy group wherein the alkoxy moiety in the 2 or 3 position may be substituted in each case by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a phenyl-C₁₋₃-alkoxy or pyridinyloxy group,

a C₅₋₇-cycloalkoxy group wherein the methylene group in the 3 or 4 position may be replaced by an -NH group, said -NH group may be substituted

by a C₁₋₃-alkyl or C₂₋₃-alkanoyl group,

by a C₂₋₃-alkanoyl or aminocarbonyl group wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, hydroxy or methoxy group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group optionally substituted by a carboxy or C₁₋₃-alkoxycarbonyl group and

R₅ denotes a cyano group or an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

or an isomer or salt thereof.

3. (amended) The compounds of formula I according to claim 1, wherein

one of the groups m or n denotes the number 0 and
the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a methyl, hydroxy, methoxy or benzyloxy group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group, or a 4- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl or pyrrolidinosulphonyl group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom or a methyl group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group substituted by a carboxy, methoxycarbonyl or ethoxycarbonyl group and

R₅ denotes an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

or an the isomers or the salts thereof.

4. (amended) A compound of the formula I according to claim 1 selected from the following compounds:

(a) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

- (b) 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,
- (c) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,
- (d) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,
- (e) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide and
- (f) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide,

wherein the amidino group may additionally be substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group, and the salts thereof.

5. (amended) A compound of formula 1 according to claim 1 as follows: 2-(5-Carbamidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and the salts thereof.
6. (amended) A pharmaceutical composition comprising a compound according to claim 1 or a physiologically acceptable salt thereof according to claim 1 wherein R₅ denotes said amidino groups.
7. (amended) Pharmaceutical compositions containing a compound according to claim 1, wherein R₅ denotes said amidino groups.
8. (amended) A method of treating a patient in need of a pharmaceutical composition having an antithrombotic activity or factor Xa inhibiting activity by administering to said patient a therapeutically effective amount of a component according to claim 1 wherein R₅ denotes said amidino groups.


Please cancel claims 9 and 10.

Please add the following new claims:

11. -- The compound according to claim 1 wherein said carboxy groups are converted into a carboxy group *in vivo* or by a group which is negatively charged under physiological conditions.
12. The compound according to claim 1 wherein said amino and imino groups are replaced by a group that may be cleaved *in vivo*.
13. A method of treating a patient in need of a pharmaceutical composition having an antithrombotic or factor Xa inhibiting activity by administering to said patient a therapeutically effective amount of a component according to claim 6.
14. Pharmaceutical compositions containing a compound according to a salt of claim 6 optionally together with one or more inert carriers and/or diluents.--

AMENDED CLAIMS MARKED TO SHOW CHANGES MADE

1. (Amended) A Carboxylic acid amides compound of the following general
formula



wherein

one of the groups m or n denotes the number 0 and

the other group m or n denotes the number 1,

Ar denotes a phenylene or naphthylene group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl, hydroxy, C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, whilst the said phenylene group may be optionally substituted by a second another fluorine, chlorine or bromine atom or by another C₁₋₃-alkyl group,

a thienylene, thiazolylene, pyridinylene, pyrimidinylene, pyrazinylene or pyridazinylene group optionally substituted in the carbon skeleton by a C₁₋₃-alkyl group,

R₁ denotes a C₁₋₃-alkyl group optionally substituted by an amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, phenyl, naphthyl, heteroaryl or 4- to 7-membered cycloalkyleneimino group,

a C₃₋₇-cycloalkyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an amino, C₁₋₅-alkylamino, C₅₋₇-cycloalkylamino or phenyl-C₁₋₃-alkylamino group which may in each case be substituted at the amino-nitrogen atom by a benzoyl or phenylsulphonyl group or by a C₁₋₃-alkyl or C₁₋₃-alkylcarbonyl group optionally substituted in the C₁₋₃-alkyl moiety by a carboxy group,

a 4- to 7-membered cycloalkyleneiminocarbonyl or cycloalkyleneiminosulphonyl group optionally substituted by a C₁₋₃-alkyl group,

an aminosulphonyl group optionally substituted by one or two C₁₋₃-alkyl groups, a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, heteroaryloxy or heteroaryloxy-C₁₋₃-alkoxy group wherein the alkoxy moiety may be substituted in the 2 or 3 position in each case by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a C₃₋₇-cycloalkoxy group, wherein whilst the methylene group in the 3 or 4 position in a C₃₋₇-cycloalkoxy group may be replaced by an -NH group, whilst and the said -NH group may be optionally substituted

by a C₁₋₃-alkyl group which may be substituted in the 2 or 3 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, by a C₁₋₃-alkylcarbonyl, arylcarbonyl or arylsulphonyl group or

by an aminocarbonyl, C₁₋₃-alkylaminocarbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group, wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, hydroxy or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group optionally substituted by a carboxy group and

R₅ denotes a cyano group or an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, whilst said by the abovementioned-heteroaryl groups consisting of ~~is meant~~ a 5-membered heteroaryl group optionally substituted by a C₁₋₃-alkyl group which contains; in the heteroaromatic moiety,

an imino group optionally substituted by a C₁₋₃-alkyl group, or an oxygen or sulphur atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen, sulphur or nitrogen atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and two nitrogen atoms or

an oxygen or sulphur atom and two nitrogen atoms,

or a 6-membered heteroarylene group optionally substituted by a C₁₋₃-alkyl group which contains one or two nitrogen atoms in the heteroaromatic moiety,

~~the carboxy groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be converted into a carboxy group *in vivo* or by a group which is negatively charged under physiological conditions or;~~

~~The amino and imino groups in the definition of the aforementioned groups are replaced by a group which may be cleaved *in vivo*~~

the an isomers and or salts thereof.

2. (amended) The C₁₋₃compounds of ~~general~~ formula I according to claim 1 wherein

one of the groups m or n denotes the number 0 and
the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a methyl, hydroxy, methoxy or benzyloxy group, which may be substituted by another methyl group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a methyl group substituted by a dimethylamino, pyrrolidino or imidazolyl group, wherein the imidazolyl moiety may be substituted by a methyl group,

an amino, C₁₋₅-alkylamino, cyclopentylamino or benzylamino group which may be substituted at the amino-nitrogen atom by a carboxy-C₁₋₂-alkyl, C₁₋₃-alkoxycarbonyl-C₁₋₂-alkyl, carboxy-C₁₋₂-alkylcarbonyl or C₁₋₃-alkoxycarbonyl-C₁₋₂-alkylcarbonyl group,

a benzoylamino or phenylsulphonylamino group,

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl, pyrrolidinosulphonyl or piperidinosulphonyl group,

a C₁₋₃-alkoxy group wherein the alkoxy moiety in the 2 or 3 position may be substituted in each case by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a phenyl-C₁₋₃-alkoxy or pyridinyloxy group,

a C₅₋₇-cycloalkoxy group wherein the methylene group in the 3 or 4 position may be replaced by an -NH group, ~~whilst the said~~ -NH group may be substituted

by a C₁₋₃-alkyl or C₂₋₃-alkanoyl group,

by a C₂₋₃-alkanoyl or aminocarbonyl group wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, hydroxy or methoxy group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group optionally substituted by a carboxy or C₁₋₃-alkoxycarbonyl group and

R₅ denotes a cyano group or an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

~~the~~ or an isomers or salts thereof.

3. (amended) ~~The~~ Compounds of ~~general~~ formula I according to claim 1, wherein

one of the groups m or n denotes the number 0 and

the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a methyl, hydroxy, methoxy or benzyloxy group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group, or a 4- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl or pyrrolidinosulphonyl group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom or a methyl group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group substituted by a carboxy, methoxycarbonyl or ethoxycarbonyl group and

R₅ denotes an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

or ~~an~~ the isomers ~~thereof~~ and or the salts thereof.

4. (amended) A compound of the ~~The following compounds of general formula I~~
according to claim 1 selected from the following compounds:

(a) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(b) 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(c) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonylethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(d) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(e) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide and

(f) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide,

wherein the amidino group may additionally be substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group, and the salts thereof.

5. (amended) A compound of formula 1 according to claim 1 as follows: 2-(5-Carbamidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and the salts thereof.

6. (amended) A pharmaceutical composition comprising a compound according to claim 1 or a ~~p~~Physiologically acceptable salts thereof according to claims 1 to 5 wherein R₅ denotes ~~one of the said amidino groups mentioned in claims 1 to 5.~~

7. (amended) Pharmaceutical compositions containing a compound according to at least one of claims 1 to 5, wherein R_5 denotes one of the said amidino groups mentioned in claims 1 to 5, or a salt according to claim 6 optionally together with one or more inert carriers and/or diluents.

8. (amended) A method of treating a patient in need of a pharmaceutical composition having an antithrombotic activity or factor Xa inhibiting activity by administering to said patient a therapeutically effective amount of a component according to Use of a compound according to at least one of claims 1 to 5, wherein R_5 denotes one of the said amidino groups mentioned in claims 1 to 5, or a salt according to claim 6, for preparing a pharmaceutical composition having an antithrombotic activity.

11. (Added) The compound according to claim 1 wherein said carboxy groups are converted into a carboxy group *in vivo* or by a group which is negatively charged under physiological conditions.

12. (Added) The compound according to claim 1 wherein said amino and imino groups are replaced by a group that may be cleaved *in vivo*.

13. (Added) A method of treating a patient in need of a pharmaceutical composition having an antithrombotic activity or factor Xa inhibiting activity by administering to said patient a therapeutically effective amount of a component according to claim 6.

14. (Added) Pharmaceutical compositions containing a compound according to a salt of claim 6 optionally together with one or more inert carriers and/or diluents.--


REMARKS

The claims have been amended to be more in conformance with standard U.S. practice. Claims 11 and 12 have been added, support being found in the original claim 1 and at page 6, lines 14-22 of the specification. Claim 7 has been redrafted as amended claim 7 and added Claim 14. The "Use" Claim 8 has been redrafted as a proper method Claim 8 and added Claim 13. There being no issues of new matter entry of these claims is respectfully requested.

Permission is hereby given to charge any additional fees to account number 02-2955.

If any points remain at issue that can best be resolved by way of telephonic or personal interview, the Examiner is kindly requested to contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,


David A. Dow
Attorney for Applicant(s)
Reg. No. 46,124

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 791-6214
Docket No.: 5/1266

"EXPRESS MAIL" LABEL NO.: EV 060 417 006 US
DEPOSIT DATE: February 6, 2002


I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE BOX PCT, ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20531.

By:


David A. Dow
Reg. No. 46,124

CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR
USE AS PHARMACEUTICAL COMPOSITIONS

The present invention relates to carboxylic acid amides of general formula



their tautomers, stereoisomers, mixtures thereof, the prodrugs thereof, the derivatives thereof which contain a group which is negatively charged under physiological conditions, and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties.

The compounds of the above general formula I wherein R_1 denotes a cyano group, are valuable intermediate products for preparing the above compounds of general formula I, and the compounds of the above general formula I wherein R_2 denotes one of the following amidino groups, as well as their tautomers, stereoisomers, mixtures thereof, the prodrugs thereof, the derivatives thereof which contain a group which is negatively charged under physiological conditions, and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids, and the stereoisomers thereof have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.

The present application thus relates to the new compounds of the above general formula I and their preparation,

Case 5/1266

pharmaceutical compositions containing the pharmacologically active compounds, the preparation and use thereof.

In the above general formula

one of the groups m or n denotes the number 0 and the other group m or n denotes the number 1,

Ar denotes a phenylene or naphthylene group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C_{1-3} -alkyl, hydroxy, C_{1-3} -alkoxy, phenyl- C_{1-3} -alkoxy, amino, C_{1-3} -alkylamino or di- $(C_{1-3}$ -alkyl)-amino group, whilst the phenylene group may be substituted by another fluorine, chlorine or bromine atom or by another C_{1-3} -alkyl group,

a thienylene, thiazolyne, pyridinyne, pyrimidinyne, pyrazinyne or pyridazinyne group optionally substituted in the carbon skeleton by a C_{1-3} -alkyl group,

R_1 denotes a C_{1-3} -alkyl group optionally substituted by an amino, C_{1-3} -alkylamino, di- $(C_{1-3}$ -alkyl)-amino, phenyl, naphthyl, heteroaryl or 4- to 7-membered cycloalkyleneimino group,

a C_{3-7} -cycloalkyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an amino, C_{1-5} -alkylamino, C_{3-7} -cycloalkylamino or phenyl- C_{1-3} -alkylamino group which may in each case be substituted at the amino-nitrogen atom by a benzoyl or phenylsulphonyl group or by a C_{1-3} -alkyl or C_{1-3} -alkylcarbonyl group optionally substituted in the C_{1-3} -alkyl moiety by a carboxy group,

Case 5/1266

a 4- to 7-membered cycloalkyleneiminocarbonyl or cycloalkyleneiminosulphonyl group optionally substituted by a C₁₋₃-alkyl group,

an aminosulphonyl group optionally substituted by one or two C₁₋₃-alkyl groups,

a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, heteroaryloxy or heteroaryloxy-C₁₋₃-alkoxy group wherein the alkoxy moiety may be substituted in the 2 or 3 position in each case by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

a C₃₋₇-cycloalkoxy group, whilst the methylene group in the 3 or 4 position in a C₃₋₇-cycloalkoxy group may be replaced by an -NH group, whilst the -NH group may be substituted

by a C₁₋₃-alkyl group which may be substituted in the 2 or 3 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, by a C₁₋₃-alkylcarbonyl, arylcarbonyl or arylsulphonyl group or

by an aminocarbonyl, C₁₋₃-alkylaminocarbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group, wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, hydroxy or C₁₋₃-alkoxy group,

Case 5/1266

R_3 denotes a hydrogen atom or a C_{1-3} -alkyl group,

R_4 denotes a hydrogen atom or a C_{1-3} -alkyl group optionally substituted by a carboxy group and

R_5 denotes a cyano group or an amidino group optionally substituted by one or two C_{1-3} -alkyl groups,

but particularly, if m, n, Ar and R_2 to R_5 are as hereinbefore defined,

R_1 denotes a C_{1-3} -alkyl group optionally substituted by an amino, C_{1-3} -alkylamino, di- $(C_{1-3}$ -alkyl)-amino, phenyl, naphthyl or heteroaryl group,

a C_{3-7} -cycloalkyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

a 4- to 7-membered cycloalkyleneiminocarbonyl group,

a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group,

a C_{1-3} -alkoxy, phenyl- C_{1-3} -alkoxy, heteroaryloxy or heteroaryloxy- C_{1-3} -alkoxy group wherein the alkoxy moiety in the 2 or 3 position may be substituted in each case by an amino, C_{1-3} -alkylamino or di- $(C_{1-3}$ -alkyl)-amino group,

a C_{3-7} -cycloalkoxy group, whilst the methylene group in the 3 or 4 position in a C_{3-7} -cycloalkoxy group may be replaced by an -NH group, whilst the -NH group may be substituted by an arylcarbonyl or arylsulphonyl group, by a C_{1-3} -alkylcarbonyl group wherein the oxygen atom of the carbonyl group may be replaced by an imino group and the alkanoyl moiety may be substituted by an amino, C_{1-3} -alkylamino or di- $(C_{1-3}$ -alkyl)-

Case 5/1266

amino group, or by a C_{1-3} -alkyl group which may be substituted in the 2 or 3 position by an amino, C_{1-3} -alkylamino or di- $(C_{1-3}$ -alkyl)-amino group,

in particular

R_1 denotes a C_{1-3} -alkyl group substituted by a 4- to 7-membered cycloalkyleneimino group,

an amino, C_{1-5} -alkylamino, C_{3-7} -cycloalkylamino or phenyl- C_{1-3} -alkylamino group which may in each case be substituted at the amino-nitrogen atom by a benzoyl or phenylsulphonyl group or by a C_{1-3} -alkyl or C_{1-3} -alkylcarbonyl group optionally substituted in the C_{1-3} -alkyl moiety by a carboxy group,

a 4- to 7-membered cycloalkyleneiminocarbonyl group substituted by a C_{1-3} -alkyl group,

a 4- to 7-membered cycloalkyleneiminosulphonyl group optionally substituted by a C_{1-3} -alkyl group,

an aminosulphonyl group optionally substituted by one or two C_{1-3} -alkyl groups,

an aminosulphonylphenyl group,

a phenyl group substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, aminosulphonyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group,

a C_{3-7} -cycloalkoxy group, whilst the methylene group in the 3 or 4 position is replaced in a C_{3-7} -cycloalkoxy group by an -NH group, whilst the -NH group is substituted

Case 5/1266

by an aminocarbonyl, C₁₋₃-alkylaminocarbonyl or di-(C₁₋₃-alkyl)-aminocarbonyl group, wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group.

By the abovementioned heteroaryl groups is meant a 5-membered heteroaryl group optionally substituted by a C₁₋₃-alkyl group which contains, in the heteroaromatic moiety,

an imino group optionally substituted by a C₁₋₃-alkyl group, or an oxygen or sulphur atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen, sulphur or nitrogen atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and two nitrogen atoms or

an oxygen or sulphur atom and two nitrogen atoms,


or a 6-membered heteroarylene group optionally substituted by a C₁₋₃-alkyl group which contains one or two nitrogen atoms in the heteroaromatic moiety.

Moreover, the carboxy groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be converted into a carboxy group *in vivo* or by a group which is negatively charged under physiological conditions or

the amino and imino groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be cleaved *in vivo*. Groups of this kind are described for example in WO 98/46576 and by N.M. Nielsen et al. in International Journal of Pharmaceutics 39, 75-85 (1987).

Case 5/1266

By a group which can be converted *in vivo* into a carboxy group is meant, for example, a hydroxymethyl group, a carboxy group esterified with an alcohol, wherein the alcoholic moiety preferably denotes a C₁₋₆-alkanol, a phenyl-C₁₋₃-alkanol, a C₃₋₉-cycloalkanol, whilst a C₃₋₈-cycloalkanol may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₈₋₈-cycloalkanol wherein a methylene group in the 3 or 4 position is replaced by an oxygen atom or by an imino group optionally substituted by a C₁₋₃-alkyl, phenyl-C₁₋₃-alkyl, phenyl-C₁₋₃-alkoxycarbonyl or C₂₋₆-alkanoyl group and the cycloalkanol moiety may additionally be substituted by one or two C₁₋₃-alkyl groups, a C₄₋₇-cycloalkenol, a C₃₋₅-alkenol, a phenyl-C₃₋₅-alkenol, a C₃₋₅-alkynol or phenyl-C₃₋₅-alkynol, with the proviso that no bond to the oxygen atom starts from a carbon atom which carries a double or triple bond, a C₃₋₈-cycloalkyl-C₁₋₃-alkanol, a bicycloalkanol having a total of 8 to 10 carbon atoms which may additionally be substituted by one or two C₁₋₃-alkyl groups in the bicycloalkyl moiety, a 1,3-dihydro-3-oxo-1-isobenzofuranol or an alcohol of formula



wherein

R_a denotes a C₁₋₈-alkyl, C₃₋₇-cycloalkyl, phenyl or phenyl-C₁₋₃-alkyl group,

R_b denotes a hydrogen atom, a C₁₋₃-alkyl, C₃₋₇-cycloalkyl or phenyl group and

R_c denotes a hydrogen atom or a C₁₋₃-alkyl group,

by a group which is negatively charged under physiological conditions is meant a tetrazol-5-yl, phenylcarbonylaminocarbonyl, trifluoromethylcarbonylaminocarbonyl,

Case 5/1266

C₁₋₆-alkylsulphonylamino, phenylsulphonylamino, benzylsulphonylamino, trifluoromethylsulphonylamino, C₁₋₆-alkylsulphonylaminocarbonyl, phenylsulphonylaminocarbonyl, benzylsulphonylaminocarbonyl or perfluoro-C₁₋₆-alkylsulphonylaminocarbonyl group

and by a group which can be cleaved *in vivo* from an imino or amino group is meant, for example, a hydroxy group, an acyl group such as a benzoyl group optionally mono- or disubstituted by fluorine, chlorine, bromine or iodine atoms or by C₁₋₃-alkyl or C₁₋₃-alkoxy groups, whilst the substituents may be identical or different, a pyridinoyl group or a C₁₋₆-alkanoyl group such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3,3,3-trichloropropionyl or allyloxycarbonyl group, a C₁₋₆-alkoxycarbonyl or C₁₋₆-alkylcarbonyloxy group wherein hydrogen atoms may be wholly or partially replaced by fluorine or chlorine atoms, such as the methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert. butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbonyl, undecyloxycarbonyl, dodecyloxycarbonyl, hexadecyloxycarbonyl, methylcarbonyloxy, ethylcarbonyloxy, 2,2,2-trichloroethylcarbonyloxy, propylcarbonyloxy, isopropylcarbonyloxy, butylcarbonyloxy, tert.butylcarbonyloxy, pentylcarbonyloxy, hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C₁₋₆-alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-amino-propionyl group wherein the amino group may be mono or disubstituted by C₁₋₆-alkyl or C₃₋₇-cycloalkyl groups and the substituents may be identical or different, a C₁₋₃-alkylsulphonyl-C₂₋₄-alkoxycarbonyl, C₁₋₃-alkoxy-C₂₋₄-alkoxy-C₂₋₄-alkoxycarbonyl, R₂-CO-O-(R₂CR₂)-O-CO, C₁₋₆-alkyl-CO-NH-(R₂CR₂)-O-CO or C₁₋₆-alkyl-

Case 5/1266

CO-O-(R_aCR_b)-(R_cCR_d)-O-CO group wherein R_a to R_d are as hereinbefore defined,

R_a and R_c, which may be identical or different, denote hydrogen atoms or C₁₋₃-alkyl groups.

Moreover, the saturated alkyl and alkoxy moieties containing more than 2 carbon atoms mentioned in the definitions given above also include the branched isomers thereof, such as the isopropyl, tert.butyl, isobutyl group, etc.

Preferred compounds of the above general formula I are those wherein

one of the groups m or n denotes the number 0 and the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a methyl, hydroxy, methoxy or benzyloxy group, which may be substituted by another methyl group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a methyl group substituted by a dimethylamino, pyrrolidino or imidazolyl group, wherein the imidazolyl moiety may be substituted by a methyl group,

an amino, C₁₋₅-alkylamino, cyclopentylamino or benzylamino group which may be substituted at the amino-nitrogen atom by a carboxy-C₁₋₂-alkyl, C₁₋₃-alkoxycarbonyl-C₁₋₂-alkyl, carboxy-

Case 5/1266

C_{1,2}-alkylcarbonyl or C_{1,3}-alkoxycarbonyl-C_{1,2}-alkylcarbonyl group,

a benzoylamino or phenylsulphonylamino group,

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl, pyrrolidinosulphonyl or piperidinosulphonyl group,

a C_{1,3}-alkoxy group wherein the alkoxy moiety in the 2 or 3 position may be substituted in each case by an amino, C_{1,3}-alkylamino or di-(C_{1,3}-alkyl)-amino group,

a phenyl-C_{1,3}-alkoxy or pyridinyloxy group,

a C_{3,7}-cycloalkoxy group wherein the methylene group in the 3 or 4 position may be replaced by an -NH group, whilst the -NH group may be substituted

by a C_{1,3}-alkyl or C_{2,3}-alkanoyl group,

by a C_{2,3}-alkanoyl or aminocarbonyl group wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, hydroxy or methoxy group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group optionally substituted by a carboxy or C_{1,3}-alkoxycarbonyl group and

Case 5/1266

R₁ denotes a cyano group or an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

the isomers thereof and the salts thereof.

Particularly preferred compounds of general formula I are those wherein

one of the groups m or n denotes the number 0 and the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a methyl, hydroxy, methoxy or benzyloxy group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group, or a 4- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl or pyrrolidinosulphonyl group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom or a methyl group,

R₃ denotes a hydrogen atom or a methyl group,

Case 5/1266

R₄ denotes a hydrogen atom or a methyl or ethyl group substituted by a carboxy, methoxycarbonyl or ethoxycarbonyl group and

R₅ denotes an amidino group optionally substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group,

the isomers thereof and the salts thereof.

The following compounds may be mentioned by way of example:

(a) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(b) 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(c) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonylethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(d) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(e) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide and


(f) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide,

wherein the amidino group may additionally be substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group, and the salts thereof.

Case 5/1266

According to the invention, the compounds of general formula I are obtained by methods known per se, e.g. by the following processes:

a) acylation of a compound of general formula



wherein

R_1 to R_4 and m are as hereinbefore defined, with a carboxylic acid of general formula



wherein

Ar , R_5 and n are as hereinbefore defined, or with the reactive derivatives thereof.

The acylation is conveniently carried out with a corresponding halide or anhydride in a solvent such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile or sulfolane, optionally in the presence of an inorganic or organic base at temperatures between -20 and 200°C , but preferably at temperatures between -10 and 160°C .


The acylation may, however, also be carried out with the free acid, optionally in the presence of an acid-activating agent or a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, hydrogen chloride, sulphuric acid,

Case 5/1266

methanesulphonic acid, p-toluenesulphonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or N,N'-thionyl-diimidazole or triphenylphosphine/carbon tetrachloride, at temperatures between -20 and 200°C, but preferably at temperatures between -10 and 160°C.

b) In order to prepare a compound of general formula I wherein R_5 denotes an amidino group which may be substituted by one or two C_{1-3} -alkyl groups:

reaction of a compound of general formula



optionally formed in the reaction mixture wherein

R_1 to R_4 , Ar and n are as hereinbefore defined and Z_1 denotes an alkoxy or aralkoxy group such as the methoxy, ethoxy, n-propoxy, isopropoxy or benzyloxy group or an alkylthio or aralkylthio group such as the methylthio, ethylthio, n-propylthio or benzylthio group, with an amine of general formula



wherein

Case 5/1266

R_6 and R_7 , which may be identical or different, each denote a hydrogen atom or a C_{1-3} -alkyl group, or with the salts thereof.

The reaction is conveniently carried out in a solvent such as methanol, ethanol, n-propanol, tetrahydrofuran or dioxane at temperatures between 0 and 150°C, preferably at temperatures between 0 and 80°C, with an amine of general formula V or with a corresponding acid addition salt such as, for example, ammonium carbonate or ammonium acetate.

A compound of general formula IV is obtained, for example, by reacting a corresponding cyano compound with a corresponding alcohol such as methanol, ethanol, n-propanol, isopropanol or benzylalcohol in the presence of an acid such as hydrochloric acid or by reacting a corresponding amide with a trialkyloxonium salt such as triethyloxonium tetrafluoroborate in a solvent such as methylene chloride, tetrahydrofuran or dioxane at temperatures between 0 and 50°C, but preferably at 20°C, or a corresponding nitrile with hydrogen sulphide, conveniently in a solvent such as pyridine or dimethylformamide and in the presence of a base such as triethylamine, and subsequently alkylating the thioamide formed with a corresponding alkyl or aralkyl halide.

If according to the invention a compound of general formula I is obtained which contains an amino or imino group, this can subsequently be converted with a corresponding acyl derivative into a corresponding acyl compound of general formula I, and/or

if a compound of general formula I is obtained which contains an esterified carboxy group, this can be converted by hydrolysis into a corresponding carboxylic acid of general formula I, and/or

Case 5/1266

if a compound of general formula I is obtained which contains a carboxy group, this can be converted by esterification into a corresponding ester.

The subsequent acylation is conveniently carried out with a corresponding halide or anhydride in a solvent such as methylene chloride, chloroform, carbon tetrachloride, ether, tetrahydrofuran, dioxane, benzene, toluene, acetonitrile or sulfolane, optionally in the presence of an inorganic or organic base at temperatures between -20 and 200°C, but preferably at temperatures between -10 and 160°C. This may also, however, be carried out with the free acid, optionally in the presence of an acid-activating agent or a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, hydrogen chloride, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide or 1-hydroxy-benzotriazole, N,N'-carbonyldiimidazole or N,N'-thionyl diimidazole or triphenylphosphine/carbon tetrachloride, at temperatures between -20 and 200°C, but preferably at temperatures between -10 and 160°C.

The subsequent hydrolysis is conveniently carried out either in the presence of an acid such as hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid or mixtures thereof or in the presence of a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as water, water/methanol, water/ethanol, water/isopropanol, methanol, ethanol, water/tetrahydrofuran or water/dioxane and the subsequent decarboxylation is carried out in the presence of an acid as hereinbefore described at temperatures between -10 and

Case 5/1266

120°C, e.g. at temperatures between ambient temperature and the boiling temperature of the reaction mixture.

The subsequent esterification is carried out with a corresponding alcohol, conveniently in a solvent or mixture of solvents such as methylene chloride, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene/tetrahydrofuran or dioxane, but preferably in an excess of the alcohol used, optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, e.g. in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, hydrochloric acid, sulphuric acid, methanesulphonic acid, p-toluenesulphonic acid, phosphorus trichloride, phosphorus pentoxide, N,N'-dicyclohexylcarbodiimide, N,N'-dicyclohexylcarbodiimide/N-hydroxysuccinimide, N,N'-carbonyldiimidazole or N,N'-thionyl-diimidazole, triphenylphosphine/carbon tetrachloride or triphenylphosphine/diethyl azodicarboxylate optionally in the presence of a base such as potassium carbonate, N-ethyl-diisopropylamine or N,N-dimethylamino-pyridine conveniently at temperatures between 0 and 150°C, preferably at temperatures between 0 and 80°C, or with a corresponding halide in a solvent such as methylene chloride, tetrahydrofuran, dioxane, dimethylsulphoxide, dimethylformamide or acetone optionally in the presence of a reaction accelerator such as sodium or potassium iodide and preferably in the presence of a base such as sodium carbonate or potassium carbonate or in the presence of a tertiary organic base such as N-ethyl-diisopropylamine or N-methyl-morpholine, which may simultaneously serve as solvent, or optionally in the presence of silver carbonate or silver oxide at temperatures between -30 and 100°C, but preferably at temperatures between -10 and 80°C.

Case 5/1266

In the reactions described hereinbefore, any reactive groups present such as hydroxy, carboxy, amino, alkylamino or imino groups may be protected during the reaction by conventional protecting groups which are cleaved again after the reaction.

For example, a protecting group for a hydroxy group may be a methoxy, benzyloxy, trimethylsilyl, acetyl, benzoyl, tert.butyl, trityl, benzyl or tetrahydropyranyl group,

protecting groups for a carboxy group may be a trimethylsilyl, methyl, ethyl, tert.butyl, benzyl or tetrahydropyranyl group and

protecting groups for an amino, alkylamino or imino group may be an acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert.butoxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2,4-dimethoxybenzyl group and additionally, for the amino group, a phthalyl group.

Any protecting group used is optionally subsequently cleaved for example by hydrolysis in an aqueous solvent, e.g. in water, isopropanol/water, tetrahydrofuran/water or dioxan/water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulphuric acid or in the presence of an alkali metal base such as lithium hydroxide, sodium hydroxide or potassium hydroxide or by ether splitting, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 100°C, preferably at temperatures between 10 and 50°C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl group is cleaved, for example, hydrogenolytically, e.g. with hydrogen in the presence of a catalyst such as palladium/charcoal in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide/acetone or glacial acetic acid, optionally with the addition of an

Case 5/1266

acid such as hydrochloric acid at temperatures between 0 and 50°C, but preferably at ambient temperature, and at a hydrogen pressure of 1 to 7 bar, but preferably 3 to 5 bar.

A methoxybenzyl group may also be cleaved in the presence of an oxidising agent such as cerium(IV) ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile/water at temperatures between 0 and 50°C, but preferably at ambient temperature.

A methoxy may conveniently be cleaved in the presence of boron tribromide in a solvent such as methylene chloride at temperatures between -35 and -25°C.

A 2,4-dimethoxybenzyl group, however, is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert.butyl or tert.butyloxycarbonyl group is preferably cleaved by treating with an acid such as trifluoroacetic acid or hydrochloric acid or by treating with iodotrimethylsilane, optionally using a solvent such as methylene chloride, dioxane, methanol or diethylether.

A phthalyl group is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene/water or dioxane at temperatures between 20 and 50°C.

An allyloxycarbonyl group is cleaved by treating with a catalytic amount of tetrakis-(triphenylphosphine)-palladium(0), preferably in a solvent such as tetrahydrofuran and preferably in the presence of an excess of a base such as morpholine or 1,3-dimethoxy at temperatures between 0 and 100°C, preferably at ambient temperature and

Case 5/1266

under inert gas, or by treating with a catalytic amount of tris-(triphenylphosphine)-rhodium(I)chloride in a solvent such as aqueous ethanol and optionally in the presence of a base such as 1,4-diazabicyclo[2.2.2]octane at temperatures between 20 and 70°C.

The compounds of general formulae II to V used as starting materials, some of which are known from the literature, are obtained by methods known from the literature, and furthermore their preparation is described in the Examples.

The chemistry of the compounds of general formula II is described, for example, by Schröter in Stickstoffverbindungen [Nitrogen compounds] II, pages 341-730, Methoden der organischen Chemie (Houben-Weyl), 4th edition, published by Thieme, Stuttgart 1957, and those of general formula III are described by J.F. Hartwig in Angew. Chem. 110, 2154-2157 (1998).

Moreover, the compounds of general formula I obtained may be resolved into their enantiomers and/or diastereomers.

Thus, for example, the compounds of general formula I obtained which occur as racemates may be separated by methods known *per se* (cf. Allinger N. L. and Eliel E. L. in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) into their optical enantiomers and compounds of general formula I with at least 2 asymmetric carbon atoms may be resolved into their diastereomers on the basis of their physical-chemical differences using methods known *per se*, e.g. by chromatography and/or fractional crystallisation, and, if these compounds are obtained in racemic form, they may subsequently be resolved into the enantiomers as mentioned above.

Case 5/1266

The enantiomers are preferably separated by column separation on chiral phases or by recrystallisation from an optically active solvent or by reacting with an optically active substance which forms salts or derivatives such as e.g. esters or amides with the racemic compound, particularly acids and the activated derivatives or alcohols thereof, and separating the diastereomeric mixture of salts or derivatives thus obtained, e.g. on the basis of their differences in solubility, whilst the free antipodes may be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Optically active acids in common use are e.g. the D- and L-forms of tartaric acid or dibenzoyltartaric acid, di-o-tolytartaric acid, malic acid, mandelic acid, camphorsulphonic acid, glutamic acid, aspartic acid or quinic acid. An optically active alcohol may be for example (+) or (-)-menthol and an optically active acyl group in amides, for example, may be a (+)- or (-)-menthyloxycarbonyl.

Furthermore, the compounds of formula I may be converted into the salts thereof, particularly for pharmaceutical use into the physiologically acceptable salts with inorganic or organic acids. Acids which may be used for this purpose include for example hydrochloric acid, hydrobromic acid, sulphuric acid, methanesulphonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

Moreover, if the new compounds of formula I contain a carboxy group, they may subsequently, if desired, be converted into the salts thereof with inorganic or organic bases, particularly for pharmaceutical use into the physiologically acceptable salts thereof. Suitable bases for this purpose include for example sodium hydroxide, potassium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

Case 5/1266

As already mentioned, the new compounds of general formula I and the salts thereof have valuable properties. Thus, the compounds of general formula I wherein R₃ denotes a cyano group are valuable intermediate products for preparing the other compounds of general formula I and the compounds of general formula I wherein R₃ denotes one of the abovementioned amidino groups and the tautomers, the stereoisomers and the physiologically acceptable salts thereof have valuable pharmacological properties, particularly an antithrombotic activity which is preferably based on an effect on thrombin or factor Xa, on a prolonging effect on aPTT time and on an inhibitory effect on related serine proteases such as e.g. trypsin, urokinase factor VIIa, factor IX, factor XI and factor XII.

For example, the compounds

A = 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride,

B = 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride,

C = 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride,

D = 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

E = 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride
and

Case 5/1266

F = 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide-hydrochloride,

were investigated for their effect on the inhibition of factor Xa as follows:

Method: Enzyme-kinetic measurement with chromogenic substrate. The quantity of anp-nitroaniline (pNA) released from the colourless chromogenic substrate by human factor Xa is determined photometrically at 405 nm. It is proportional to the activity of the enzyme used. The inhibition of the enzyme activity by the test substance I (in relation to the solvent control) is determined at various concentrations of test substance and from this the IC_{50} is calculated, as the concentration which inhibits the factor Xa used by 50 %.

Material:

Tris(hydroxymethyl)-aminomethane buffer (100 mmol) of and sodium chloride (150 mMol), pH 8.0

Factor Xa (Roche), spec. activity: 10 U/0.5 ml, final concentration: 0.175 U/ml per reaction mixture

Substrate Chromozym X (Roche), final concentration: 200 μ Mol/l per reaction mixture

Test substance: final concentration 100, 30, 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 μ Mol/l

Procedure: 10 μ l of a 23.5-times concentrated starting solution of the test substance or solvent (control), 175 μ l of tris(hydroxymethyl)-aminomethane buffer and 25 μ l of Factor Xa working solution of 1.65 U/ml are incubated for 10 minutes at 37°C. After the addition of 25 μ l of Chromozym X

Case 5/1266

working solution (1.88 $\mu\text{Mol/l}$) the sample is measured in a photometer (SpectraMax 250) at 405 nm for 150 seconds at 37°C.

Evaluation:

1. Determining the maximum increase ($\Delta\text{OD}/\text{minutes}$) over 3 measuring points.
2. Determining the % inhibition based on the solvent control.
3. Plotting a dosage/activity curve (% inhibition vs substance concentration).
4. Determining the IC_{50} by interpolating the X value (substance concentration) of the dosage/activity curve at Y = 50 % inhibition.

The following Table shows the results obtained:

substance	inhibition of factor Xa (IC_{50} in μM)
A	0.030
B	0.680
C	0.120
D	0.850
E	0.085
F	0.260

The compounds prepared according to the invention are well tolerated, as no toxic side effects could be observed at therapeutic doses.

In view of their pharmacological properties the new compounds and the physiologically acceptable salts thereof

Case 5/1266

are suitable for the prevention and treatment of venous and arterial thrombotic diseases, such as for example the treatment of deep leg vein thrombosis, for preventing reocclusions after bypass operations or angioplasty (PT(C)A), and occlusion in peripheral arterial diseases such as pulmonary embolism, disseminated intravascular coagulation, for preventing coronary thrombosis, stroke and the occlusion of shunts. In addition, the compounds according to the invention are suitable for antithrombotic support in thrombolytic treatment, such as for example with rt-PA or streptokinase, for preventing long-term restenosis after PT(C)A, for preventing metastasis and the growth of clot-dependent tumours and fibrin-dependent inflammatory processes, e.g. in the treatment of pulmonary fibrosis.

The dosage required to achieve such an effect is appropriately 0.1 to 30 mg/kg, preferably 0.3 to 10 mg/kg by intravenous route, and 0.1 to 50 mg/kg, preferably 0.3 to 30 mg/kg by oral route, in each case administered 1 to 4 times a day. For this purpose, the compounds of formula I prepared according to the invention may be formulated, optionally together with other active substances, with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, glucose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethyleneglycol, propyleneglycol, cetylstearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof, to produce conventional galenic preparations such as plain or coated tablets, capsules, powders, suspensions or suppositories.

The Examples which follow are intended to illustrate the invention:

Case 5/1266

10049196.100902

Case 5/1266

Example 1

2-(3-carbamimidoyl-phenyl)-N-[2-chloro-5-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-phenyl]-acetamide-hydrochloride

a. 1-(4-chloro-3-nitro-phenyl)-cyclopropanecarboxylic acid
350 ml of fuming nitric acid are combined at -25 to -30°C with 50.0 g (0.21 mol) of 1-(4-chloro-phenyl)-cyclopropanecarboxylic acid in batches. After it has all been added the mixture is stirred for a further 15 minutes at -25°C and then poured onto ice. The substance precipitated is suction filtered, washed with water and dried.

Yield: 58.5 g (95 % of theory),

R_f value: 0.43 (silica gel; methylene chloride/methanol = 9.5:0.5)

b. 5-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-2-chloro-nitrobenzene

2.4 g (0.01 mol) of 1-(4-chloro-3-nitro-phenyl)-cyclopropanecarboxylic acid are dissolved in 25 ml of tetrahydrofuran and after the addition of 3.2 g (0.01 mol) of O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, 1.1 ml of (0.01 mol) of N-methyl-morpholine and 1.0 ml of (0.012 mol) of pyrrolidine stirred for 16 hours at ambient temperature. The solvent is distilled off, the residue is poured onto ice water, made alkaline with ammonia and extracted with ethyl acetate. The organic phase is dried and evaporated down.

Yield: 2.5 g (85 % of theory),

R_f value: 0.18 (silica gel; cyclohexane/ethyl acetate = 1:1)

c. 5-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-2-chloro-aniline

Case 5/1266

1.8 g (8.14 mmol) of 5-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-2-chloro-nitrobenzene are dissolved in 30 ml of ethyl acetate and 30 ml of ethanol and after the addition of 0.8 g palladium on active charcoal (10%) hydrogenated for 3 hours at ambient temperature with hydrogen. Then the catalyst is filtered off and the filtrate is evaporated down.

Yield: 2.0 g (92.8 % of theory),

R_f value: 0.24 (silica gel; cyclohexane/ethyl acetate/ammonia = 1:1:0.01)

C₁₄H₁₇ClN₂O (264.75)

mass spectrum: M⁺ = 264/6 (Cl)

d. 2-(3-cyano-phenyl)-N-[2-chloro-5-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-phenyl]-acetamide

Prepared analogously to Example 1b from 5-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-2-chloro-aniline, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate, N-methyl-morpholine and 3-cyanophenylacetic acid in dimethylformamide.

Yield: 43 % of theory,

R_f value: 0.21 (silica gel; cyclohexane/ethyl acetate = 1:2)

e. 2-(3-carbamimidoyl-phenyl)-N-[2-chloro-5-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-phenyl]-acetamide-hydrochloride
400 mg (0.1 mmol) of 2-(3-cyano-phenyl)-N-[2-chloro-5-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-phenyl]-acetamide are dissolved in 60 ml of saturated ethanolic hydrochloric acid and stirred for 17 hours at ambient temperature. The solvent is distilled off, the residue is dissolved in 50 ml of absolute ethanol and mixed with 1.5 g (15.6 mmol) of ammonium carbonate. After 22 hours at ambient temperature the mixture is evaporated to dryness. The residue is

Case 5/1266

chromatographed on silica gel, eluting with methylene chloride/methanol/glacial acetic acid (9:1:0.01).

Yield: 50 mg (11 % of theory),

R_f value: 0.59 (silica gel; methylene

chloride/methanol/ammonia = 4:1:0.01)

C₂₃H₂₅ClN₄O₂ x HCl (424.94/461.4)

mass spectrum: (M+H)⁺ = 425/7 (Cl)

Case 5/1266

Example 23-carbamimidoyl-N-[3-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-benzyl]-benzamide-hydrochloridea. 1-(3-bromo-phenyl)-1-cyclopropane-nitril

25 g (0.13 mol) of 3-bromo-benzylcyanide are taken up in 32 ml (0.38 mol) of 1-bromo-2-chloro-ethane and combined with 0.6 g (2.6 mmol) of benzyltriethylammonium chloride. Then a solution of 105.8 g (2.65 mol) of sodium hydroxide in 106 ml of water is added dropwise at 10 to 25°C. After 20 hours at 55°C the reaction solution is poured onto ice water and extracted with ethyl acetate. The organic extracts are dried and evaporated down. The residue is triturated with petroleum ether, suction filtered and dried.

Yield: 19.3 g (68 % of theory),

R_f value: 0.69 (petroleum ether/ethyl acetate = 4:1)

b. 1-(3-bromo-phenyl)-cyclopropanecarboxylic acid

7.6 g (0.135 mol) of potassium hydroxide are dissolved in 60 ml of ethyleneglycol, combined batchwise with 10.0 g (0.045 mol) of 1-(3-bromo-phenyl)-1-cyclopropane-nitrile and after the addition of 30 ml of water heated to 140°C for 4.5 hours. After cooling it is poured onto 600 ml of ice water and extracted with ether. The aqueous phase is poured onto ice/conc. hydrochloric acid, the product precipitated is suction filtered and dried.

Yield: 10.1 g (93 % of theory),

R_f value: 0.85 (silica gel; cyclohexane/ethyl acetate/glacial acetic acid = 1:1:0.01)

c. 3-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-bromo-benzene

Prepared analogously to Example 1b' from 1-(3-bromo-phenyl)-cyclopropanecarboxylic acid, pyrrolidine, O-(benzotriazol-1-

Case 5/1266

yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and N-methyl-morpholine in tetrahydrofuran.

Yield: 98 % of theory,

R_f value: 0.55 (silica gel; cyclohexane/ethyl

acetate/glacial acetic acid = 1:1:0.01)

d. 3-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-benzonitrile

6 g (20.4 mmol) of 3-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-bromo-benzene are dissolved in 25 ml of dimethylformamide and after the addition of 2.7 g (30.6 mmol) of copper-I-cyanide, 0.3 g (0.216 mmol) of tetrakis-triphenylphosphine-palladium-(0) and 5 g of aluminium oxide stirred for 30 hours at 140°C. The insoluble matter is filtered off and the solution is evaporated down. The residue is chromatographed on silica gel, eluting with cyclohexane/ethyl acetate (1:2).

Yield: 1.8 g (36 % of theory),

R_f value: 0.32 (silica gel; cyclohexane/ethyl

acetate/glacial acetic acid = 1:1:0.01)

e. 3-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-benzylamine

1.8 g (7.5 mmol) of 3-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-benzonitrile are hydrogenated with hydrogen in 50 ml of methanolic ammonia with the addition of 300 mg Raney nickel for 3 hours at 70°C. Then the catalyst is filtered off and the filtrate is evaporated down.

Yield: 1.8 g (98 % of theory),

R_f value: 0.94 (silica gel; methylene chloride

/methanol/ammonia = 4:1:0.01)

f. 3-cyano-N-[3-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-benzyl]-benzamide

Prepared analogously to Example 1b from 3-[1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl]-benzylamine, 3-cyanobenzoic acid, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium

Case 5/1266

tetrafluoroborate and N-methyl-morpholine in tetrahydrofuran.

Yield: 96 % of theory,

R_f value: 0.56 (silica gel; ethyl acetate/ethanol = 9:1)

g. 3-carbamimidoyl-N-[3-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-benzyl]-benzamide-hydrochloride

Prepared analogously to Example 1e from 3-cyano-N-[3-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-benzyl]-benzamide and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 58 % of theory,

R_f value: 0.19 (Reversed phase RP 8; 5% sodium chloride solution/methanol = 1:1)

C₂₃H₂₆N₄O₂ x HCl (390.48/426.95)

mass spectrum: (M+H)⁺ = 391

(M-H+HCl)⁺ = 425/7 (Cl)

The following compounds are prepared analogously to Example 2:

(1) 3-carbamimidoyl-N-[4-(1-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-benzyl]-benzamide-hydrochloride

Yield: 68 % of theory,

C₂₃H₂₆N₄O₂ x HCl (390.48/426.95)

mass spectrum: (M+H)⁺ = 391

(M+2H)⁺⁺ = 196

(2) 5-carbamimidoyl-2-hydroxy-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-benzyl]-benzamide-hydrochloride

Yield: 34% of theory,

R_f value: 0.1 (Reversed phase RP8; 5% saline solution/methanol = 1:1)

C₂₃H₂₄N₄O₃ x HCl (380.46/416.91)

mass spectrum: (M+H)⁺ = 381

Case 5/1266

10049106.100902

$(M-H)^+ = 379$

Case 5/1266

Example 3

2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[2-methyl-5-(1-(pyrrolidin-1-carbonyl)-cyclopropyl)-phenyl]-acetamide-hydrochloride

a. 5-cyano-2-methoxy-phenylacetic acid

Prepared analogously to Example 2d from 5-bromo-2-methoxy-phenylacetic acid, copper-I-cyanide, tetrakis-triphenylphosphine-palladium-(0) and aluminium oxide in dimethylformamide.

Yield: 37 % of theory,

R_f value: 0.26 (silica gel; cyclohexane/ethyl acetate/glacial acetic acid = 1:1:0.01)

b. 2-(5-cyano-2-methoxy-phenyl)-N-[2-methyl-5-(1-(pyrrolidin-1-carbonyl)-cyclopropyl)-phenyl]-acetamide

0.6 g (3.3 mmol) of 5-cyano-2-methoxy-phenylacetic acid are dissolved in 10 ml of dimethylformamide and after the addition of 0.5 g (3.3 mmol) of N,N-carbonyldiimidazole stirred for 10 minutes at ambient temperature. Then 0.8 g (3.3 mmol) of 5-(pyrrolidin-1-yl-carbonyl)-cyclopropyl)-2-methyl-aniline are added. The reaction mixture is stirred for 4 hours at 80°C, cooled to ambient temperature, combined with ice water, made alkaline with ammonia and extracted several times with ethyl acetate. The combined organic extracts are dried and evaporated down. The residue is chromatographed on silica gel, eluting with cyclohexane/ethyl acetate (7:3).

Yield: 73 % of theory,

R_f value: 0.30 (silica gel; ethyl acetate)

Case 5/1266

c. 2-(5-cyano-2-hydroxy-phenyl)-N-[2-methyl-5-(1-(pyrrolidin-1-carbonyl)-cyclopropyl)-phenyl]-acetamide

0.7 g (1.67 mmol) of 2-(5-cyano-2-methoxy-phenyl)-N-[2-methyl-5-(1-(pyrrolidin-1-carbonyl)-cyclopropyl)-phenyl]-acetamide are dissolved in 35 ml of methylene chloride and at -35 to -25°C 10 ml of a 1-molar solution of boron tribromide in methylene chloride (10 mmol) are added dropwise. After 1 hour's stirring at 20°C, first ice is added, then 20 ml of 2N hydrochloric acid. The aqueous phase is extracted several times with methylene chloride, the combined organic extracts are dried and evaporated down. The residue is chromatographed on silica gel, eluting with methylene chloride/ethanol (100:1).

Yield: 81 % of theory,

R_f value: 0.14 (silica gel; methylene chloride/ethanol = 49:1)

d. 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[2-methyl-5-(1-(pyrrolidin-1-carbonyl)-cyclopropyl)-phenyl]-acetamide-hydrochloride

Prepared analogously to Example 1e from 2-(5-cyano-2-hydroxy-phenyl)-N-[2-methyl-5-(1-(pyrrolidin-1-carbonyl)-cyclopropyl)-phenyl]-acetamide, and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 80 % of theory,

R_f value: 0.39 (silica gel; methylene

chloride/methanol/glacial acetic acid = 4:1:0.01)

C₂₄H₂₈N₄O₃ x HCl (420.51/456.98)

mass spectrum: (M+H)⁺ = 421

(M+Cl)⁺ = 455/7 (Cl)

The following compound is prepared analogously to Example 3:

Case 5/1266

(1) 2-(5-carbamimidoyl-2-methoxy-phenyl)-N-[2-methyl-5-(1-(pyrrolidin-1-carbonyl)-cyclopropyl)-phenyl]-acetamide-hydrochloride

Yield: 92 % of theory,

R_f value: 0.33 (silica gel; methylene

chloride/methanol/glacial acetic acid = 4:1:0.01)

C₂₅H₃₀N₄O₃ × HCl (434.55/471.01)

mass spectrum: (M+H)⁺ = 435

Case 5/1266

Example 4

2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

a. 2-(5-cyano-2-methoxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

0.4 g (2 mmol) of 3-methyl-4-(pyrrolidin-1-yl-carbonyl)-aniline are dissolved in 15 ml of tetrahydrofuran and after the addition of 0.3 ml (2 mmol) of triethylamine and 0.4 g (2 mmol) of 5-cyano-3-methoxy-phenylacetic acid chloride stirred for 48 hours at ambient temperature. Then the mixture is combined with water, made alkaline with ammonia and extracted with ethyl acetate. The combined organic extracts are washed with 1N hydrochloric acid, dried and evaporated down.

Yield: 0.45 g (59 % of theory),

R_f value: 0.18 (silica gel; ethyl acetate)

b. 2-(5-carbamimidoyl-2-methoxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

Prepared analogously to Example 1e from 2-(5-cyano-2-methoxyphenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 36 % of theory,

R_f value: 0.33 (Reversed phase RP 8; 5% sodium chloride solution/methanol = 1:1)

C₂₂H₂₆N₄O₃ x HCl (394.48/430.94)

mass spectrum: (M+H)⁺ = 395

(M-H+HCl)⁺ = 429

c. 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

Case 5/1266

Prepared analogously to Example 3c from 2-(5-carbamimidoyl-2-methoxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride and boron tribromide in dichloromethane.

Yield: 19 % of theory,

R_f value: 0.38 (Reversed phase RP 8; 5% sodium chloride solution/methanol = 1:1)

$C_{21}H_{24}N_4O_3 \times HCl$ (380.45/416.91)

mass spectrum: $(M+H)^+ = 381$

$(M-H)^- = 379$

The following compounds are prepared analogously to Example 4:

(1) 2-(3-carbamimidoyl-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

Yield: 12 % of theory,

$C_{21}H_{24}N_4O_2 \times HCl$ (364.45/400.92)

mass spectrum: $(M+H)^+ = 365$

(2) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-methyl-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

Yield: 99 % of theory,

$C_{22}H_{26}N_4O_3 \times HCl$ (394.48/430.94)

mass spectrum: $(M+H)^+ = 395$

$(M-H)^- = 393$

(3) 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-methyl-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

Yield: 90 % of theory,

$C_{29}H_{32}N_4O_3 \times HCl$ (484.60/521.06)

mass spectrum: $(M+H)^+ = 485$

$(M-H+HCl)^- = 519/21$ (Cl)

Case 5/1266

(4) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(N-(3-ethoxycarbonyl-propionyl)-N-cyclopentyl-amino)-phenyl]-acetamide-hydrochloride

Yield: 74% of theory,

$C_{27}H_{34}N_6O_5 \times HCl$ (494.61/531.06)

R_f value: 0.36 (Reversed phase RP8; 5% saline solution/methanol = 4:6)

Case 5/1266

mass spectrum: $(M+H)^+ = 495$
 $(M+Cl)^+ = 529/531$ (Cl)
 $(M-H)^+ = 493$

(5) 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-[3-methyl-4-(N-(3-ethoxycarbonyl-propionyl)-N-(2-methyl-propyl)-amino)-phenyl]-acetamide-hydrochloride
 Yield: 74% of theory,

R_f value: 0.21 (silica gel; methylene chloride/ethanol = 4:1)

$C_{33}H_{40}N_4O_5 \times HCl$ (572.71/609.18)

mass spectrum: $(M+H)^+ = 573$
 $(M-H)^+ = 571$

(6) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(N-(3-ethoxycarbonyl-propionyl)-N-(2-methyl-propyl)-amino)-phenyl]-acetamide-hydrochloride

Yield: 100% of theory,

R_f value: 0.33 (Reversed phase RP8; 5% saline solution/methanol = 4:6)

$C_{26}H_{34}N_4O_5 \times HCl$ (482.58/519.05)

mass spectrum: $(M+H)^+ = 483$
 $(M-H)^+ = 481$
 $(M+Cl)^+ = 517/519$ (Cl)

(7) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(N-ethoxycarbonylacetyl-N-cyclopentyl-amino)-phenyl]-acetamide-hydrochloride

(8) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-sulphonyl)-phenyl]-acetamide-hydrochloride

Case 5/1266

Example 5

2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

a. 2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-bromobenzene

Prepared analogously to Example 1b from 4-bromo-3,5-dimethyl-benzoic acid, pyrrolidine, O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate and triethylamine in dimethylformamide.

Yield: 63 % of theory,

R_f value: 0.45 (silica gel; methylene chloride/ethanol = 19:1)

b. 2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-benzylaniline

2.3 g (0.01 mol) of 2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-bromobenzene and 1.3 g (0.012 mol) of benzylamine are dissolved in 25 ml of toluene and after the addition of 4.6 g of caesium carbonate, 100 mg palladium-II-acetate and 200 mg 2,2'-bis(-diphenylphosphino)-1,1'-binaphthyl stirred for 7 hours under an argon atmosphere at 100°C. After cooling the mixture is diluted with ice water and extracted with ethyl acetate. The combined organic extracts are dried and evaporated down. The residue is chromatographed on silica gel, eluting with methylene chloride/ethanol (50:1 and 25:1).

Yield: 60 % of theory,

R_f value: 0.30 (silica gel; methylene chloride/ethanol = 9:1)

c. 2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-aniline

Prepared analogously to Example 1c from 2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-benzylaniline and palladium on active charcoal in methanol.

Yield: 94 % of theory,

Case 5/1266

R_f value: 0.30 (silica gel; ethyl acetate/petroleum ether =
1:1)

Case 5/1266

d. 2-benzyloxy-5-bromo-phenylacetic acid

A solution of 12.4 g (0.053 mol) of 2-hydroxy-5-bromo-phenylacetic acid in 125 ml of dimethylformamide is combined with 14 g (0.125 mol) of potassium tert.butoxide. After 15 minutes at ambient temperature 18.5 g (0.108 mol) of benzylbromide are added. The reaction solution is stirred for 3 hours at ambient temperature, poured onto ice water and extracted with ethyl acetate. The combined organic extracts are dried and evaporated down. The residue is dissolved in 100 ml of ethanol and after the addition of 50 ml of 2N sodium hydroxide solution stirred for 3 hours at ambient temperature. The solvent is distilled off, the residue is adjusted to pH 4 with 2N hydrochloric acid. After extraction with ethyl acetate the organic phases are dried and evaporated down. The residue is chromatographed on silica gel and eluted with petroleum ether/ethyl acetate (8:2).

Yield: 6.7 g (38 % of theory),

R_f value: 0.50 (silica gel; ethyl acetate/petroleum ether = 1:1)

e. 2-benzyloxy-5-cyano-phenylacetic acid

Prepared analogously to Example 2d from 2-benzyloxy-5-bromo-phenylacetic acid, copper-I-cyanide, tetrakis-triphenylphosphine-palladium-(0) and aluminium oxide in dimethylformamide.

Yield: 26 % of theory,

R_f value: 0.45 (silica gel; methylene chloride/ethanol = 19:1)

f. 2-(5-cyano-2-benzyloxy-phenyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

Prepared analogously to Example 1b from 2-benzyloxy-5-cyano-phenylacetic acid, 2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-aniline, O-(benzotriazol-1-yl)-N,N,N',N'-

Case 5/1266

tetramethyluroniumtetrafluoroborate and N-methylmorpholine in tetrahydrofuran.

Yield: 44 % of theory,

R_f value: 0.75 (silica gel; ethyl acetate/ethanol = 9:1)

g. 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

Prepared analogously to Example 1e from 2-(5-cyano-2-benzyloxy-phenyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 86 % of theory,

R_f value: 0.20 (silica gel; methylene

chloride/ethanol/glacial acetic acid = 8:2:0.01)

h. 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

355 mg (0.68 mmol) of 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-[2,5-dimethyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide are dissolved in 40 ml of methanol and after the addition of 250 mg of palladium on active charcoal the mixture is hydrogenated with hydrogen for 15 minutes. Then the catalyst is filtered off and the filtrate is evaporated down.

Yield: 145 mg (49 % of theory),

R_f value: 0.10 (silica gel; methylene

chloride/ethanol/glacial acetic acid = 8:2:0.01)

C₂₂H₂₆N₄O₃ · x HCl (394.48/430.94)

mass spectrum: (M+H)⁺ = 395

(M-H)⁻ = 393

The following compounds are prepared analogously to Example 5:

Case 5/1266

(1) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride
Yield: 98% of theory,

R_f value: 0.75 (Reversed phase RP8; 5% saline solution/methanol = 1:4)

C₂₂H₂₆N₄O₃ x HCl (394.49/430.94)

mass spectrum: M⁺ = 395
(M+Cl)⁺ = 429/431 (Cl)
(M-H)⁺ = 393

(2) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-methyl-pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

Yield: 100% of theory,

R_f value: 0.7 (Reversed phase RP8; 5% saline solution/methanol = 1:4)

C₂₂H₂₆N₄O₃ x HCl (394.49/430.94)

mass spectrum: M⁺ = 395
(M+Cl)⁺ = 429/431 (Cl)
(M-H)⁺ = 393

Example 6

2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

a. N-(2-methoxycarbonyl-ethyl)-3-methyl-4-(pyrrolidin-1-yl-carbonyl)-aniline

1.5 g (7.3 mmol) of 3-methyl-4-(pyrrolidin-1-yl-carbonyl)-aniline, 20 ml of (220 mmol) of methyl acrylate, 1 ml (2.2 mmol) of Triton B and 60 mg (0.27 mmol) of 2,5-di-tert.butyl-hydroquinone are stirred for 22 hours at 85°C. Then the reaction mixture is evaporated down, the residue is

Case 5/1266

chromatographed on silica gel, eluting with methylene chloride + 0 to 5 % ethanol.

Yield: 1.6 g (76 % of theory),

R_f value: 0.70 (silica gel; methylene chloride/ethanol = 9:1)

b. 2-(2-benzyloxy-5-cyano-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

0.8 g (2.88 mmol) of N-(2-methoxycarbonyl-ethyl)-3-methyl-4-(pyrrolidin-1-yl-carbonyl)-aniline are dissolved in 50 ml of tetrahydrofuran and after the addition of 1.1 ml (7.86 mmol) of triethylamine and 0.8 g (2.62 mmol) of 2-benzyloxy-5-cyano-phenylacetic acid chloride stirred for 8 hours at ambient temperature. Then the mixture is diluted with water and extracted with methylene chloride. The combined organic extracts are dried and evaporated down. The residue is chromatographed on silica gel, eluting with methylene chloride.

Yield: 1.0 g (71 % of theory),

R_f value: 0.72 (silica gel; methylene chloride/ethanol = 9:1)

c. 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

Prepared analogously to Example 1e from 2-(2-benzyloxy-5-cyano-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 44 % of theory,

R_f value: 0.17 (silica gel; methylene chloride/ethanol = 4:1)

C₃₃H₃₈N₄O₅ x HCl (570.69/607.16)

Case 5/1266

mass spectrum: $(M+H)^+ = 571$

Example 7

2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride

Prepared analogously to Example 5h from 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride and palladium on active charcoal in methanol.

Yield: 96 % of theory,

R_f value: 0.45 (Reversed phase RP 8; methanol/5% sodium chloride solution = 6:4)

C₂₆H₃₂N₄O₃ x HCl (480.57/517.04)

mass spectrum: $(M+H)^+ = 481$

Case 5/1266

Example 8

2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-
N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-
hydrochloride

0.3 g (0.58 mmol) of 2-(2-hydroxy-5-carbamimidoyl-phenyl)-
N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-
carbonyl)-phenyl]-acetamide-hydrochloride are stirred into a
mixture of 3.2 ml (3.2 mmol) of 1-molar lithium hydroxide
solution, 6.2 ml of water and 7.6 ml of tetrahydrofuran for
2 hours at ambient temperature. After the addition of 74 mg
ammonium chloride the solution is evaporated down. The
residue is chromatographed on the reversed phase and eluted
with water.

Yield: 0.2 g (71 % of theory),

R_f value: 0.62 (Reversed phase RP 8; methanol/5% sodium
chloride solution = 6:4)

C₂₅H₂₈N₄O₅ x HCl (452.52/488.97)

mass spectrum: (M+H)⁺ = 453

(M-H)⁻ = 451

The following compounds are prepared analogously to Example
8:

(1) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-
4-(N-(3-carboxypropionyl)-N-cyclopentyl-amino)-phenyl]-
acetamide-hydrochloride

Yield: 83% of theory,

C₂₅H₃₀N₄O₅ x HCl (466.55/503.01)

R_f value: 0.84 (Reversed phase RP8; 5% saline solution/metha-
nol = 6:4)

(2) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-
4-(N-carboxyacetyl-N-cyclopentyl-amino)-phenyl]-acetamide-
hydrochloride

Case 5/1266

Case 5/1266

Example 9

3-carbamimidoyl-N-[4-(pyrrolidin-3-yl-oxy)-benzyl]-
benzamide-dihydrochloride

a. N-tert.butyloxycarbonyl-3-pyrrolidinol

5.8 g (66.5 mmol) of 3-pyrrolidinol and 6.7 g (67 mmol) of triethylamine are dissolved in 80 ml of methylene chloride and a solution of 15.3 g (70 mmol) of di-tert.butyl-dicarbonate in 40 ml of methylene chloride is added dropwise. After 16 hours at ambient temperature the mixture is stirred with water, the organic phase is dried and evaporated down.

Yield: 12.4 g (100 % of theory),

R_f value: 0.75 (silica gel; ethyl acetate/methanol = 9:1)

b. 4-[(N-tert.butyloxycarbonyl)-pyrrolidin-3-yl-oxy]-benzonitrile

3.8 g (20 mmol) of N-tert.butyloxycarbonyl-3-pyrrolidinol are dissolved in 100 ml of tetrahydrofuran and after the addition of 2.4 g (20 mmol) of 4-hydroxybenzonitrile, 5.7 g (22 mmol) of triphenylphosphine and 3.9 g (22 mmol) of diethyl diethylazodicarboxylate the mixture is stirred for 18 hours at ambient temperature. The solvent is distilled off and the residue is chromatographed on silica gel, eluting with cyclohexane/ethyl acetate (10:5).

Yield: 4.5 g (78 % of theory),

R_f value: 0.40 (silica gel; cyclohexane/ethyl acetate = 10:5)

c. 4-[(N-tert.butyloxycarbonyl)-pyrrolidin-3-yl-oxy]-benzylamine

4.5 g (15.6 mmol) of 4-[(N-tert.butyloxycarbonyl)-pyrrolidin-3-yl-oxy]-benzonitrile are dissolved in 100 ml of

Case 5/1266

methanol and 50 ml of methanolic ammonia and after the addition of 1 g of Raney nickel hydrogenated for 2 hours at 50°C with hydrogen. Then the catalyst is filtered off and the filtrate is evaporated down.

Yield: 4.2 g (92 % of theory),

R_f value: 0.08 (silica gel; ethyl acetate/methanol = 4:1)

d. 3-cyano-N-[4-(N'-tert.butyloxycarbonyl-pyrrolidin-3-yl-oxy)-benzyl]-benzamide

1.1 g (3.8 mmol) of 4-[(N-tert.butyloxycarbonyl)-pyrrolidin-3-yl-oxy]-benzylamine are dissolved in 30 ml of methylene chloride and after the addition of 0.9 g (9 mmol) of triethylamine, 1.6 g (3.8 mmol) of 3-cyanobenzoic acid chloride are added batchwise. After 4 hours at ambient temperature the solution is combined with water, the organic phase is dried and evaporated down.

Yield: 1.5 g (94 % of theory),

R_f value: 0.27 (silica gel; methylene chloride/ethyl acetate = 9:1)

e. 3-carbamimidoyl-N-[4-(pyrrolidin-3-yl-oxy)-benzyl]-benzamide-dihydrochloride

Prepared analogously to Example 1e from 3-cyano-N-[4-(N'-tert.butyloxycarbonyl-pyrrolidin-3-yl-oxy)-benzyl]-benzamide and hydrochloric acid/ammonium chloride in ethanol.

Yield: 100 % of theory,

Melting point: from 180°C (decomposition)

C₁₉H₂₂N₄O₂ x 2 HCl (338.41/411.41)

mass spectrum: (M+H)⁺ = 339

The following compounds are prepared analogously to Example 9:

(1) 3-carbamimidoyl-N-[4-(cyclopentyloxy)-benzyl]-benzamide-hydrochloride

Case 5/1266

Yield: 86 % of theory

R_f value: 0.42 (silica gel; methylene chloride/ethanol = 8:2)

$C_{20}H_{19}N_3O_2 \times HCl$ (337.43/373.89)

mass spectrum: (M+H)⁺ = 338

(2) 3-carbamimidoyl-N-[4-(benzyloxy)-benzyl]-benzamide-hydrochloride

Yield: 63 % of theory

R_f value: 0.28 (silica gel; methylene chloride/ethanol = 17:1)

$C_{22}H_{21}N_3O_2 \times HCl$ (359.43/395.89)

mass spectrum: (M+H)⁺ = 360

(3) 3-carbamimidoyl-N-[4-(N'-acetyl-pyrrolidin-3-yl-oxy)-benzyl]-benzamide-hydrochloride

Yield: 100 % of theory,

R_f value: 0.08 (silica gel; methylene chloride/ethanol = 9:1)

$C_{21}H_{24}N_4O_2 \times HCl$ (380.45/416.91)

mass spectrum: (M+H)⁺ = 381

(4) 3-carbamimidoyl-N-[4-(N'-methyl-pyrrolidin-3-yl-oxy)-benzyl]-benzamide-hydrochloride

Yield: 29 % of theory,

R_f value: 0.07 (silica gel; methylene chloride/ethanol = 7:3)

$C_{20}H_{24}N_4O_2 \times HCl$ (352.44/388.91)

mass spectrum: (M+H)⁺ = 353

(5) 3-carbamimidoyl-N-[4-(N'-(aminomethylcarbonyl)-pyrrolidin-3-yl-oxy)-benzyl]-benzamide-dihydrochloride

Yield: 82 % of theory,

Melting point: from 160°C (decomposition)

$C_{21}H_{23}N_5O_2 \times 2 HCl$ (395.54/468.46)

Case 5/1266

mass spectrum: $(M+H)^+ = 396$

(6) 3-carbamimidoyl-N-[4-(N'-(2-aminoethyl-carbonyl)-pyrrolidin-3-yl-oxy)-benzyl]-benzamide-dihydrochloride

Yield: 88 % of theory,

Melting point: from 165°C (decomposition)

$C_{22}H_{27}N_5O_3 \times 2 HCl$ (409.48/482.48)

mass spectrum: $(M+H)^+ = 410$

(7) 3-carbamimidoyl-N-[4-(3-amino-propyloxy)-benzyl]-benzamide-dihydrochloride

Yield: 82 % of theory,

Melting point: from 122°C (decomposition)

$C_{18}H_{22}N_4O_2 \times 2 HCl$ (326.40/399.4)

mass spectrum: $(M+H)^+ = 327$

(8) 3-carbamimidoyl-N-[4-(2-dimethylamino-ethyloxy)-benzyl]-benzamide-dihydrochloride

Yield: 85 % of theory,

Melting point: from 65°C (decomposition)

$C_{19}H_{24}N_4O_2 \times 2 HCl$ (340.43/413.43)

mass spectrum: $(M+H)^+ = 341$

(9) 3-carbamimidoyl-N-[4-(pyridin-4-yl-oxy)-benzyl]-benzamide-hydrochloride

Yield: 66 % of theory,

Melting point: 115°C (decomposition)

$C_{20}H_{18}N_4O_2 \times HCl$ (346.39/382.89)

mass spectrum: $(M+H)^+ = 347$

(10) 3-carbamimidoyl-N-[4-(piperidin-4-yl-oxy)-benzyl]-benzamide-hydrochloride

Yield: 62 % of theory

Melting point: from 170°C (decomposition)

$C_{20}H_{24}N_4O_2 \times HCl$ (352.44/388.89)

mass spectrum: $(M+H)^+ = 353$

Case 5/1266

Example 10

3-carbamimidoyl-N-[4-(1-(1-imino-ethyl)-pyrrolidin-3-yl-oxy)-benzyl]-benzamide-dihydrochloride

a. 3-cyano-N-[4-(pyrrolidin-3-yl-oxy)-benzyl]-benzamide

2.4 g (5.7 mmol) of 3-cyano-N-[4-(N-tert.butyloxycarbonyl-pyrrolidin-3-yl-oxy)-benzyl]-benzamide are dissolved in 30 ml of methylene chloride and at 0°C combined with 8 ml of trifluoroacetic acid. After 1 hour at ambient temperature the solvent is distilled off, the residue is taken up in methylene chloride, made alkaline with ammonia and water is added. The combined organic extracts are dried and evaporated down.

Yield: 1.4 g (76 % of theory),

R_f value: 0.29 (silica gel; methylene chloride/methanol/ammonia = 7:3:0.2)

b. 3-cyano-N-[4-(1-(1-imino-ethyl)-pyrrolidin-3-yl-oxy)-benzyl]-benzamide

0.7 g (2.17 mmol) of 3-cyano-N-[4-(pyrrolidin-3-yl-oxy)-benzyl]-benzamide, 0.4 g (3.2 mmol) of ethyl acetimidate hydrochloride and 1 g (10 mmol) of triethylamine are dissolved in 70 ml of ethanol and the mixture is stirred for 6 days at ambient temperature. The solvent is distilled off, the residue is taken up in water and made alkaline with sodium carbonate. Then it is extracted with methylene chloride, the combined organic extracts are dried and evaporated down. The residue is triturated with ether and suction filtered.

Yield: 0.6 g (76 % of theory),

R_f value: 0.37 (silica gel; methylene chloride/methanol/ammonia = 7:3:0.2)

Case 5/1266

Melting point: from 80°C (decomposition)

c. 3-carbamimidoyl-N-[4-(1-(1-imino-ethyl)-pyrrolidin-3-yl-oxy)-benzyl]-benzamide-dihydrochloride

Prepared analogously to Example 1e from 3-cyano-N-[4-(1-(1-imino-ethyl)-pyrrolidin-3-yl-oxy)-benzyl]-benzamide and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 64 % of theory,

Melting point: from 100°C (decomposition)

$C_{21}H_{25}N_5O_2 \times 2 HCl$ (379.46/452.46)

mass spectrum: $(M+H)^+ = 380$

The following compound is prepared analogously to Example 10:

(1) 3-carbamimidoyl-N-[4-(1-carbamimidoyl-pyrrolidin-3-yl-oxy)-benzyl]-benzamide-dihydrochloride

Yield: 88 % of theory,

Melting point: from 160°C (decomposition)

$C_{20}H_{24}N_6O_2 \times 2 HCl$ (380.45/453.38)

mass spectrum: $(M+2H)^+ = 191$

Example 11

3-carbamimidoyl-N-[4-(benzoylamino)-benzyl]-benzamide-hydrochloride

a. 3-cyano-N-(4-amino-benzyl)-benzamide

6 g (0.05 mol) of 4-aminobenzylamine and 10 g (0.1 mol) of triethylamine are dissolved in 150 ml of methylene chloride and at ambient temperature a solution of 8.3 g (0.05 mol) of 3-cyanobenzoylchloride in 20 ml of methylene chloride is added dropwise. After one hour 150 ml of water and 20 ml of methanol are added. After extraction the combined organic extracts are dried and evaporated down. The residue is chromatographed on silica gel and eluted with ethyl acetate.

Case 5/1266

Yield: 4.4 g (35 % of theory),
 R_f value: 0.69 (silica gel; ethyl acetate)

b. 3-cyano-N-[4-(benzoylamino)-benzyl]-benzamide

A solution of 0.6 g (4.2 mmol) of benzoylchloride in 10 ml of methylene chloride is added dropwise to a solution of 1 g (4 mmol) of 3-cyano-N-(4-amino-benzyl)-benzamide and 0.6 g (6 mmol) of triethylamine in 30 ml of methylene chloride at ambient temperature. After 8 hours at ambient temperature the product which has crystallised out is dissolved in methylene chloride and methanol. After extraction with water the combined organic extracts are dried and evaporated down. Yield: 1.2 g (84 % of theory),
 Melting point: 210°C

c. 3-carbamimidoyl-N-[4-(benzoylamino)-benzyl]-benzamide-hydrochloride

Prepared analogously to Example 1e from 3-cyano-N-[4-(benzoylamino)-benzyl]-benzamide and hydrochloric acid/ammonium carbonate in ethanol.
 Yield: 65 % of theory,
 Melting point: 190-215°C
 $C_{22}H_{20}N_4O_2 \times HCl$ (372.43/408.93)
 mass spectrum: $(M+H)^+ = 373$

The following compounds are prepared analogously to Example 11:

(1) 3-carbamimidoyl-N-[4-(phenylsulphonylamino)-benzyl]-benzamide-hydrochloride

Yield: 80 % of theory,
 Melting point: 266°C
 $C_{21}H_{20}N_4O_2S \times HCl$ (408.48/444.98)
 mass spectrum: $(M+H)^+ = 409$

Case 5/1266

(2) 3-carbamimidoyl-N-[4-(benzylamino)-benzyl]-benzamide-hydrochloride

Yield: 69 % of theory,

$C_{22}H_{22}N_4O \times HCl$ (358.44/394.94)

mass spectrum: $(M+H)^+ = 359$

(3) 3-carbamimidoyl-N-[4-(N-benzyl-N-ethoxycarbonylmethyl-amino)-benzyl]-benzamide-hydrochloride

Yield: 79 % of theory,

Melting point: from 100°C

$C_{26}H_{28}N_4O_2 \times HCl$ (444.54/481.04)

mass spectrum: $(M+H)^+ = 445$

(4) 3-carbamimidoyl-N-[4-biphenyl-methyl]-benzamide

Yield: 79 % of theory,

Melting point: from 160°C (decomposition)

$C_{21}H_{19}N_3O$ (329.40)

mass spectrum: $(M+H)^+ = 330$

(5) 3-carbamimidoyl-N-[4-(cyclopentylamino)-benzyl]-benzamide-hydrochloride

Yield: 80 % of theory,

Melting point: from 135°C (decomposition)

$C_{20}H_{24}N_4O \times HCl$ (336.44/372.94)

mass spectrum: $M^+ = 336$

Example 12

3-carbamimidoyl-N-(4-dimethylaminomethyl-benzyl)-benzamide-dihydrochloride

a. 4-cyano-N,N-dimethyl-benzylamine

A solution of 7.3 g (0.16 mol) of dimethylamine in 100 ml of ether is added dropwise at -5°C to a solution of 10 g (0.05 mol) of 4-cyanobenzylbromide in 400 ml of ether. Then the

Case 5/1266

reaction mixture is stirred for 2 hours at -5°C and for 20 hours at ambient temperature. After the addition of 200 ml of water and 200 ml of conc. hydrochloric acid the aqueous solution is separated off, made alkaline with sodium hydroxide solution and extracted with methylene chloride. The combined organic extracts are dried and evaporated down. Yield: 8 g (100 % of theory),
 R_f value: 0.58 (silica gel; methylene chloride/ethanol = 9:1)

b. 4-dimethylaminomethyl-benzylamine

Prepared analogously to Example 9c from 4-cyano-N,N-dimethyl-benzylamine, methanolic ammonia and Raney nickel/hydrogen.

Yield: 94 % of theory,
 R_f value: 0.13 (silica gel; methylene chloride/ethanol = 9:1)

c. 3-cyano-N-(4-dimethylaminomethyl-benzyl)-benzamide

Prepared analogously to Example 9d from 4-dimethylaminomethyl-benzylamine, 3-cyanobenzoylchloride and triethylamine in methylene chloride.

Yield: 73 % of theory,
Melting point: 100°C

Case 5/1266

d. 3-carbamimidoyl-N-(4-dimethylaminomethyl-benzyl)-
benzamide-dihydrochloride

Prepared analogously to Example 1e from 3-cyano-N-(4-dimethylaminomethyl-benzyl)-benzamide and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 100 % of theory,

Melting point: from 101°C (decomposition)

$C_{18}H_{22}N_4O \times 2 HCl$ (310.40/383.40)

mass spectrum: $(M+H)^+ = 311$

The following compounds are prepared analogously to Example 12:

(1) 3-carbamimidoyl-N-[4-(imidazol-1-yl)-methyl-benzyl]-
benzamide-hydrochloride

Yield: 86 % of theory,

Melting point: from 152°C (decomposition)

$C_{19}H_{19}N_5O \times HCl$ (333.39/369.89)

mass spectrum: $(M+H)^+ = 334$

(2) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-methyl)-phenyl]-acetamide-dihydrochloride

Yield: 60 % of theory

R_f value (reversed phase RP8; 5% saline solution / methanol = 2:3): 0.7

$C_{21}H_{26}N_4O_2 \times 2 HCl$ (366.47/439.38)

mass spectrum: $(M+H)^+ = 367$

$(M-H)^- = 365$

(3) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(imidazol-1-yl-methyl)-phenyl]-acetamide-dihydrochloride

Yield: 57 % of theory

R_f value (reversed phase RP8; 5% saline solution / methanol = 2:3): 0.7

$C_{20}H_{21}N_5O_2 \times 2 HCl$ (363.42/436.33)

Case 5/1266

mass spectrum: $(M+H)^+ = 364$
 $(M-H)^- = 362$

(4) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-methyl-imidazol-1-yl-methyl)-phenyl]-acetamide-dihydrochloride

Example 13

2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-amino-sulphonyl-phenyl)-phenyl]-acetamide-hydrochloride

a. 3-Allyl-4-hydroxy-benzonitrile

82.3 g (0.52 mol) of 4-allyloxy-benzonitrile are heated to 200°C for 2 hours under a nitrogen atmosphere. After cooling, the crude product is purified on silica gel, eluting first with petroleum ether, later with petroleum ether/ethyl acetate (9:1, 8:2, 7:3 and 1:1). The uniform fractions are combined and evaporated down, the residue is washed with petroleum ether and dried.

Yield: 43 g (52% of theory),

R_f value: 0.45 (silica gel; petroleum ether/ethyl acetate = 1:1)

$C_{10}H_9NO$ (159.19)

mass spectrum: $(M-H)^- = 158$
 $(2M+Na)^+ = 341$

b. 3-Allyl-4-benzyloxy-benzonitrile

Prepared analogously to Example 5d from 3-allyl-4-hydroxy-benzonitrile and benzylbromide/potassium carbonate in dimethylformamide.

Yield: 90% of theory,

Melting point: 59-60°C

R_f value: 0.55 (silica gel; petroleum ether/ethyl acetate = 4:1)

Case 5/1266

c. 2-benzyloxy-5-cyano-phenylacetic acid

30 g (0.12 mol) of 3-allyl-4-benzyloxy-benzonitrile are dissolved in 450 ml of acetonitrile and at 40°C 0.7 g of ruthenium trichloride hydrate and a solution of 179.7 g (0.84 mol) of sodium periodate in 1 litre of water is added. After it has all been added, the reaction mixture is heated to 40°C for a further 30 minutes and then extracted 3 x with 1 litre of ethyl acetate. The organic phases are washed with saline solution and dried over sodium sulphate. The crude product is recrystallised from petroleum ether/ethyl acetate (7:3) with the addition of activated charcoal.

Yield: 18.4 g (58% of theory),

Melting point: 144-145°C

R_f value: 0.2 (silica gel; petroleum ether/ethyl acetate = 1:1)

C₁₆H₁₃NO₃ (267.29)

Case 5/1266

mass spectrum: $(M-H)^+ = 266$
 $(M+Na)^+ = 290$

d. 2-(5-cyano-2-benzyloxy-phenyl)-N-[3-methyl-4-(2-
tert.butylaminosulphonyl-phenyl)-phenyl]-acetamide

Prepared analogously to Example 1b from 2-benzyloxy-5-cyano-phenylacetic acid and 4'-amino-2'-methyl-biphenyl-2-sulphonic acid-tert.-butylamide/O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate/triethylamine in dimethylformamide.

Yield: 60% of theory,

R_f value: 0.5 (silica gel; methylene chloride/ethanol = 19:1)

e. 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide-hydrochloride

Prepared analogously to Example 1e from 2-(5-cyano-2-benzyloxy-phenyl)-N-[3-methyl-4-(2-tert.butylaminosulphonyl-phenyl)-phenyl]-acetamide and hydrochloric acid/ammonium carbonate in ethanol.

Yield: 70% of theory,

R_f value: 0.3 (silica gel; methylene chloride/ethanol = 9:1 + 1% glacial acetic acid)

$C_{29}H_{32}N_6O_5S \times HCl$ (528.63/565.08)

mass spectrum: $(M-H)^+ = 527$
 $(M+H)^+ = 529$

f. 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide-hydrochloride

Prepared analogously to Example 5h from 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide-hydrochloride and hydrogen/palladium on activated charcoal.

Yield: 62% of theory,

R_f value: 0.45 (Reversed phase RP8; 5% saline solution/methanol = 1:1)

$C_{22}H_{22}N_6O_5S \times HCl$ (438.52/474.97)

10049196.100906

Case 5/1266

Case 5/1266

mass spectrum: $(M+H)^+ = 439$
 $(M+Cl)^+ = 473/5$ (Cl)

The following compounds are prepared analogously to Example 13:

(1) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-(3-methyl-4-phenyl-phenyl)-acetamide-hydrochloride

Yield: 13% of theory,

R_f value: 0.15 (silica gel; methylene chloride/ethanol = 4:1)

$C_{22}H_{21}N_3O_2 \times HCl$ (359.45/395.9)

mass spectrum: $(M+H)^+ = 360$

$(M-H)^+ = 358$

(2) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-5-methyl-phenyl)-phenyl]-acetamide-hydrochloride

Yield: 23 % of theory

R_f value (silica; methylene chloride / ethanol = 7:3): 0.3

$C_{24}H_{24}N_4O_4S \times HCl$ (452.54/488.99)

mass spectrum: $(M+H)^+ = 453$

$(M-H)^+ = 451$

Example 14

2-[5-(N-benzoyl-carbamimidoyl)-2-hydroxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

a. 2-[5-(N-benzoyl-carbamimidoyl)-2-benzyloxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

350 mg (0.69 mmol) of 2-(5-carbamimidoyl-2-benzyloxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-hydrochloride are suspended in 40 ml of methylene chloride and combined with 1.0 ml of triethylamine and 300

Case 5/1266

mg (1.3 mmol) of 4-nitrophenylbenzoate. The reaction mixture is refluxed for 4 hours. After the addition of 100 ml of saline solution the aqueous phase is extracted 3 x with methylene chloride. The combined organic phases are dried over sodium sulphate and concentrated by evaporation. The crude product is purified on silica gel, eluting first with methylene chloride, then with methylene chloride/ethanol (50:1 and 19:1). The uniform fractions are combined, concentrated by evaporation and stirred with petroleum ether/ether (1:1). The solid formed is suction filtered and dried.

Yield: 280 mg (71% of theory),

R_f value: 0.2 (silica gel; petroleum ether/ethyl acetate = 1:1)

$C_{35}H_{36}N_4O_4$ (574.69)

mass spectrum: $(M-H)^+ = 573$

$(M+H)^+ = 575$

b. 2-[5-(N-benzoyl-carbamimidoyl)-2-hydroxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

Prepared analogously to Example 5h from 2-[5-(N-benzoyl-carbamimidoyl)-2-benzyloxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and hydrogen/palladium on activated charcoal.

Yield: 31% of theory,

R_f value: 0.3 (silica gel; methylene chloride/ethanol = 19:1)

$C_{28}H_{28}N_4O_4$ (484.56)

mass spectrum: $(M+H)^+ = 485$

$(M+Na)^+ = 507$

The following compounds are prepared analogously to Example 14:

(1) 2-[5-(N-n-hexyloxycarbonyl-carbamimidoyl)-2-hydroxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

Case 5/1266

Yield: 17% of theory,

R_f value: 0.3 (silica gel; methylene chloride/ethanol = 4:1)

$C_{28}H_{30}N_4O_5$ (508.62)

mass spectrum: $(M+H)^+ = 509$

$(M-H)^- = 507$

(2) 2-[5-(N-benzoyl-carbamimidoyl)-2-methoxy-phenyl]-

N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

Yield: 40% of theory,

R_f value: 0.3 (silica gel; methylene chloride/ethanol = 19:1)

$C_{29}H_{30}N_4O_4$ (498.59)

mass spectrum: $(M+H)^+ = 499$

$(M-H)^- = 497$

(3) 2-[5-(N-n-hexyloxycarbonyl-carbamimidoyl)-2-methoxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

Yield: 35% of theory,

R_f value: 0.25 (silica gel; methylene chloride/ethanol = 19:1)

$C_{29}H_{38}N_4O_5$ (522.65)

mass spectrum: $(M+H)^+ = 523$

$(M-H)^- = 521$

$(M+Na)^+ = 545$

(4) 2-[5-(N-ethyloxycarbonyl-carbamimidoyl)-2-methoxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide

Yield: 32% of theory,

R_f value: 0.45 (silica gel; methylene chloride/ethanol = 9:1)

$C_{25}H_{30}N_4O_5$ (466.54)

mass spectrum: $(M+H)^+ = 467$

$(M-H)^- = 465$

$(M+Na)^+ = 489$

Case 5/1266

Example 15

2-[5-(N-hydroxy-carbamimidoyl)-2-hydroxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-acetate

a. 2-[5-(N-hydroxy-carbamimidoyl)-2-benzyloxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-acetate

1.1 g (2.5 mmol) of 2-(5-cyano-2-benzyloxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide are dissolved in 100 ml of methanol and combined with a solution of 300 mg (5 mmol) of hydroxylamine hydrochloride in 2.0 ml of water. After the addition of 800 mg (2.5 mmol) of caesium carbonate and 300 mg (3.0 mmol) of sodium carbonate the reaction mixture is refluxed for 6 hours. After cooling and the addition of 0.5 l of ice water the crude product obtained is suction filtered and purified on silica gel, eluting first with methylene chloride and methylene chloride/ethanol (19:1), then with methylene chloride/ethanol (9:1 + 1% glacial acetic acid and 4:1 + 1% glacial acetic acid). The uniform fractions are combined and concentrated by evaporation.

Yield: 620 mg (51% of theory),

R_f value: 0.3 (silica gel; methylene chloride/ethanol = 9:1)

$C_{28}H_{30}N_6O_4$ (486.58)

mass spectrum: $(M-H)^- = 485$

$(M+H)^+ = 487$

$(M+Na)^+ = 509$

b. 2-[5-(N-hydroxy-carbamimidoyl)-2-hydroxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-acetate

Prepared analogously to Example 5h from 2-[5-(N-hydroxy-carbamimidoyl)-2-benzyloxy-phenyl]-N-[3-methyl-4-

Case 5/1266

(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-acetate and hydrogen/palladium on activated charcoal.

Yield: 50% of theory,

R_f value: 0.25 (silica gel; methylene chloride/ethanol = 4:1 + 1% glacial acetic acid)

$C_{22}H_{26}N_4O_4 \times CH_3COOH$ (396.45/456.5)

mass spectrum: $(M+H)^+ = 397$

$(M-H)^- = 395$

The following compound is prepared analogously to Example 15:

(1) 2-[5-(N-hydroxy-carbamimidoyl)-2-methoxy-phenyl]-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide-acetate

Yield: 7% of theory,

R_f value: 0.28 (silica gel; methylene chloride/ethanol = 4:1 + 1% glacial acetic acid)

$C_{22}H_{26}N_4O_4 \times CH_3COOH$ (410.48/470.52)

mass spectrum: $(M+H)^+ = 411$

$(M-H)^- = 409$

$(M+Na)^+ = 433$

Example 16

Dry ampoule containing 75 mg of active substance per 10 ml

Composition:

Active substance	75.0 mg
Mannitol	50.0 mg
water for injections	ad 10.0 ml

Preparation:

Case 5/1266

Active substance and mannitol are dissolved in water. After packaging the solution is freeze-dried. To produce the solution ready for use, the product is dissolved in water for injections.

Example 17

Dry ampoule containing 35 mg of active substance per 2 ml

Composition:

Active substance	35.0 mg
Mannitol	100.0 mg
water for injections	ad 2.0 ml

Preparation:

Active substance and mannitol are dissolved in water. After packaging, the solution is freeze-dried.

To produce the solution ready for use, the product is dissolved in water for injections.

Example 18

Tablet containing 50 mg of active substance

Composition:

(1) Active substance	50.0 mg
(2) Lactose	98.0 mg
(3) Maize starch	50.0 mg
(4) Polyvinylpyrrolidone	15.0 mg

Case 5/1266

(5) Magnesium stearate	<u>2.0 mg</u>
	215.0 mg

Preparation:

(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.

Diameter of the tablets: 9 mm.

Example 19

Tablet containing 350 mg of active substance

Composition:

(1) Active substance	350.0 mg
(2) Lactose	136.0 mg
(3) Maize starch	80.0 mg
(4) Polyvinylpyrrolidone	30.0 mg
(5) Magnesium stearate	<u>4.0 mg</u>
	600.0 mg

Preparation:

(1), (2) and (3) are mixed together and granulated with an aqueous solution of (4). (5) is added to the dried granulated material. From this mixture tablets are pressed, biplanar, faceted on both sides and with a dividing notch on one side.

Diameter of the tablets: 12 mm.

Example 20

Case 5/1266

Capsules containing 50 mg of active substance

Composition:

(1) Active substance	50.0 mg
(2) Dried maize starch	58.0 mg
(3) Powdered lactose	50.0 mg
(4) Magnesium stearate	<u>2.0 mg</u>
	160.0 mg

Preparation:

(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing.

This powder mixture is packed into size 3 hard gelatine capsules in a capsule filling machine.

Example 21

Capsules containing 350 mg of active substance

Composition:

(1) Active substance	350.0 mg
(2) Dried maize starch	46.0 mg
(3) Powdered lactose	30.0 mg
(4) Magnesium stearate	<u>4.0 mg</u>
	430.0 mg

Preparation:

(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with vigorous mixing.

This powder mixture is packed into size 0 hard gelatine capsules in a capsule filling machine.

Case 5/1266

Example 22

Suppositories containing 100 mg of active substance

1 suppository contains:

Active substance	100.0 mg
Polyethyleneglycol (M.W. 1500)	600.0 mg
Polyethyleneglycol (M.W. 6000)	460.0 mg
Polyethylenesorbitan monostearate	<u>840.0 mg</u>
	2,000.0 mg


Preparation:

The polyethyleneglycol is melted together with polyethylenesorbitan monostearate. At 40°C the ground active substance is homogeneously dispersed in the melt. This is then cooled to 38°C and poured into slightly chilled suppository moulds.

Case 5/1266

Patent Claims

1. Carboxylic acid amides of general formula



wherein

one of the groups m or n denotes the number 0 and
the other group m or n denotes the number 1,

Ar denotes a phenylene or naphthylene group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, C₁₋₃-alkyl, hydroxy, C₁₋₃-alkoxy, phenyl-C₁₋₃-alkoxy, amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, whilst the phenylene group may be substituted by another fluorine, chlorine or bromine atom or by another C₁₋₃-alkyl group,

a thienylene, thiazolylene, pyridinylen, pyrimidinylene, pyrazinylen or pyridazinylene group optionally substituted in the carbon skeleton by a C₁₋₃-alkyl group,

R₁ denotes a C₁₋₃-alkyl group optionally substituted by an amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, phenyl, naphthyl, heteroaryl or 4- to 7-membered cycloalkyleneimino group,

a C₃₋₇-cycloalkyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an amino, C₁₋₅-alkylamino, C₃₋₇-cycloalkylamino or phenyl-C₁₋₃-alkylamino group which may in each case be substituted at the amino-nitrogen atom by a benzoyl or phenylsulphonyl

Case 5/1266

group or by a C_{1-3} -alkyl or C_{1-3} -alkylcarbonyl group optionally substituted in the C_{1-3} -alkyl moiety by a carboxy group,

a 4- to 7-membered cycloalkyleneiminocarbonyl or cycloalkyleneiminosulphonyl group optionally substituted by a C_{1-3} -alkyl group,

an aminosulphonyl group optionally substituted by one or two C_{1-3} -alkyl groups,

a phenyl group optionally substituted by a fluorine, chlorine or bromine atom, by a trifluoromethyl, aminosulphonyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkoxy group,

a C_{1-3} -alkoxy, phenyl- C_{1-3} -alkoxy, heteroaryloxy or heteroaryloxy- C_{1-3} -alkoxy group wherein the alkoxy moiety may be substituted in the 2 or 3 position in each case by an amino, C_{1-3} -alkylamino or di- $(C_{1-3}$ -alkyl)-amino group,

a C_{3-7} -cycloalkoxy group, whilst the methylene group in the 3 or 4 position in a C_{3-7} -cycloalkoxy group may be replaced by an -NH group, whilst the -NH group may be substituted

by a C_{1-3} -alkyl group which may be substituted in the 2 or 3 position by an amino, C_{1-3} -alkylamino or di- $(C_{1-3}$ -alkyl)-amino group, by a C_{1-3} -alkylcarbonyl, arylcarbonyl or arylsulphonyl group or

by an aminocarbonyl, C_{1-3} -alkylaminocarbonyl or di- $(C_{1-3}$ -alkyl)-aminocarbonyl group, wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

Case 5/1266

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom, a C₁₋₃-alkyl, hydroxy or C₁₋₃-alkoxy group,

R₃ denotes a hydrogen atom or a C₁₋₃-alkyl group,

R₄ denotes a hydrogen atom or a C₁₋₃-alkyl group optionally substituted by a carboxy group and

R₅ denotes a cyano group or an amidino group optionally substituted by one or two C₁₋₃-alkyl groups, whilst

by the abovementioned heteroaryl groups is meant a 5-membered heteroaryl group optionally substituted by a C₁₋₃-alkyl group which contains, in the heteroaromatic moiety,

an imino group optionally substituted by a C₁₋₃-alkyl group, or an oxygen or sulphur atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and an oxygen, sulphur or nitrogen atom,

an imino group optionally substituted by a C₁₋₃-alkyl group and two nitrogen atoms or

an oxygen or sulphur atom and two nitrogen atoms,

or a 6-membered heteroarylene group optionally substituted by a C₁₋₃-alkyl group which contains one or two nitrogen atoms in the heteroaromatic moiety,

the carboxy groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be converted into a carboxy group *in vivo* or by a group which is negatively charged under physiological conditions or

Case 5/1266

the amino and imino groups mentioned in the definition of the abovementioned groups may be replaced by a group which may be cleaved *in vivo*,

the isomers and salts thereof.

2. Compounds of general formula I according to claim 1, wherein

one of the groups m or n denotes the number 0 and the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a fluorine, chlorine or bromine atom or by a methyl, hydroxy, methoxy or benzyloxy group, which may be substituted by another methyl group,

R₁ denotes a phenyl group optionally substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may additionally be substituted by a fluorine, chlorine or bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group,

a methyl group substituted by a dimethylamino, pyrrolidino or imidazolyl group, wherein the imidazolyl moiety may be substituted by a methyl group,

an amino, C₁₋₅-alkylamino, cyclopentylamino or benzylamino group which may be substituted at the amino-nitrogen atom by a carboxy-C₁₋₂-alkyl, C₁₋₃-alkoxycarbonyl-C₁₋₂-alkyl, carboxy-C₁₋₂-alkylcarbonyl or C₁₋₃-alkoxycarbonyl-C₁₋₂-alkylcarbonyl group,

a benzoylamino or phenylsulphonylamino group,

Case 5/1266

a cyclopropyl group which is substituted in the 1 position by a 5- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl, piperidinocarbonyl, pyrrolidinosulphonyl or piperidinosulphonyl group,

a C_{1-3} -alkoxy group wherein the alkoxy moiety in the 2 or 3 position may be substituted in each case by an amino, C_{1-3} -alkylamino or di- $(C_{1-3}$ -alkyl)-amino group,

a phenyl- C_{1-3} -alkoxy or pyridinyloxy group,

a C_{5-7} -cycloalkoxy group wherein the methylene group in the 3 or 4 position may be replaced by an -NH group, whilst the -NH group may be substituted

by a C_{1-3} -alkyl or C_{2-3} -alkanoyl group,

by a C_{2-3} -alkanoyl or aminocarbonyl group wherein in each case the oxygen atom of the carbonyl group is replaced by an imino group,

R_1 denotes a hydrogen, fluorine, chlorine or bromine atom, a methyl, hydroxy or methoxy group,

R_2 denotes a hydrogen atom or a methyl group,

R_3 denotes a hydrogen atom or a methyl or ethyl group optionally substituted by a carboxy or C_{1-3} -alkoxycarbonyl group and

R_4 denotes a cyano group or an amidino group optionally substituted by a C_{1-6} -alkoxycarbonyl or benzoyl group,

the isomers thereof and the salts thereof.

Case 5/1266

3. Compounds of general formula I according to claim 1,
wherein

one of the groups m or n denotes the number 0 and
the other group m or n denotes the number 1,

Ar denotes a phenylene group optionally substituted by a
methyl, hydroxy, methoxy or benzyloxy group,

R₁ denotes a phenyl group optionally substituted by a
fluorine, chlorine or bromine atom or by a trifluoromethyl,
aminosulphonyl, C₁₋₃-alkyl or C₁₋₃-alkoxy group, which may
additionally be substituted by a fluorine, chlorine or
bromine atom or by a trifluoromethyl, C₁₋₃-alkyl or C₁₋₃-alkoxy
group,

a cyclopropyl group which is substituted in the 1 position
by a 5- to 7-membered cycloalkyleneiminocarbonyl group, or a
4- to 7-membered cycloalkyleneiminocarbonyl group,

an optionally methyl-substituted pyrrolidinocarbonyl,
piperidinocarbonyl or pyrrolidinosulphonyl group,

R₂ denotes a hydrogen, fluorine, chlorine or bromine atom or
a methyl group,

R₃ denotes a hydrogen atom or a methyl group,

R₄ denotes a hydrogen atom or a methyl or ethyl group
substituted by a carboxy, methoxycarbonyl or ethoxycarbonyl
group and

R₅ denotes an amidino group optionally substituted by a
C₁₋₆-alkoxycarbonyl or benzoyl group,

Case 5/1266

the isomers thereof and the salts thereof.

4. The following compounds of general formula I according to claim 1:

(a) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(b) 2-(2-benzyloxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonyl-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(c) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-ethoxycarbonylethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(d) 2-(2-hydroxy-5-carbamimidoyl-phenyl)-N-(2-carboxy-ethyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide,

(e) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(piperidin-1-yl-carbonyl)-phenyl]-acetamide and

(f) 2-(5-carbamimidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(2-aminosulphonyl-phenyl)-phenyl]-acetamide,

wherein the amidino group may additionally be substituted by a C₁₋₆-alkoxycarbonyl or benzoyl group, and the salts thereof.

5. 2-(5-Carbamidoyl-2-hydroxy-phenyl)-N-[3-methyl-4-(pyrrolidin-1-yl-carbonyl)-phenyl]-acetamide and the salts thereof.

6. Physiologically acceptable salts of the compounds according to claims 1 to 5 wherein R₃ denotes one of the amidino groups mentioned in claims 1 to 5.

Case 5/1266


7. Pharmaceutical compositions containing a compound according to at least one of claims 1 to 5, wherein R_5 denotes one of the amidino groups mentioned in claims 1 to 5, or a salt according to claim 6 optionally together with one or more inert carriers and/or diluents.

8. Use of a compound according to at least one of claims 1 to 5, wherein R_5 denotes one of the amidino groups mentioned in claims 1 to 5, or a salt according to claim 6, for preparing a pharmaceutical composition having an anti-thrombotic activity.

9. Process for preparing a pharmaceutical composition according to claim 7, characterised in that a compound according to at least one of claims 1 to 5, wherein R_5 denotes one of the amidino groups mentioned in claims 1 to 5, or a salt according to claim 6 is incorporated in one or more inert carriers and/or diluents by a non-chemical method.

10. Process for preparing the compounds according to claims 1 to 6, characterised in that


a) a compound of general formula



wherein

R_1 to R_4 and m are defined as in claims 1 to 5, is acylated with a carboxylic acid of general formula


Case 5/1266



wherein

Ar, R₅ and n are defined as in claims 1 to 5, or with the reactive derivatives thereof, or

b) in order to prepare a compound of general formula I wherein R₅ denotes an amidino group which may be substituted by one or two C₁₋₃-alkyl groups, a compound of general formula



optionally formed in the reaction mixture, wherein

R₁ to R₄, Ar and n are defined as in claims 1 to 5 and Z₁ denotes an alkoxy, aralkoxy, alkylthio or aralkylthio group, is reacted with an amine of general formula



wherein

R₆ and R₇, which may be identical or different, each denote a hydrogen atom or a C₁₋₃-alkyl group, or with the salts thereof, and

subsequently, if desired, a compound of general formula I thus obtained which contains an amino or imino group is converted by means of a corresponding acyl derivative into a corresponding acyl compound of general formula I and/or

Case 5/1266

a compound of general formula I thus obtained which contains an esterified carboxy group is converted by hydrolysis into a corresponding carboxylic acid of general formula I and/or

a compound of general formula I thus obtained which contains a carboxy group is converted by esterification into a corresponding ester and/or

a protecting group used to protect reactive groups during the reactions is cleaved and/or


a compound of general formula I thus obtained is resolved into the stereoisomers thereof, and/or

a compound of general formula I thus obtained is converted into the salts thereof, particularly, for pharmaceutical use, into the physiologically acceptable salts thereof with an inorganic or organic acid or base.

Case 5/1266

Abstract

The present invention relates to carboxylic acid amides of general formula



wherein

R_1 to R_5 , Ar, m and n are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof, the prodrugs and the salts thereof which have valuable properties.

The compounds of the above general formula I wherein R_4 denotes a cyano group are valuable intermediate products for preparing the other compounds of general formula I, and the compounds of the above general formula I wherein R_4 denotes one of the amidino groups mentioned in claim 1 have valuable pharmacological properties, particularly an antithrombotic activity and a factor Xa-inhibiting activity.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63) <input type="checkbox"/> Declaration Submitted with Initial Filing OR <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)		Attorney Docket Number	5/1266
		First Named Inventor	Uwe RIES et al
		COMPLETE IF KNOWN	
		Application Number	10 / 049,196
		Filing Date	to be assigned
		Group Art Unit	to be assigned
		Examiner Name	to be assigned

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

CARBOXYLIC ACID AMIDES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS

 the specification of which
☐ is attached hereto
 OR
☒ was filed on (MM/DD/YYYY) 08/02/2000

(Title of the invention)

as United States Application Number or PCT International

Application Number PCT/EP00/07457 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?
100 25 663.5	Germany	05/24/2000	<input type="checkbox"/>	<input type="checkbox"/>
199 37 494.5	Germany	08/07/1999	<input type="checkbox"/>	<input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below:

Application Number(s)	Filing Date (MM/DD/YYYY)	
		<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☒

Approved for use through 9/30/00. OMB 0651-0032
 Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith: ☐ Customer Number ☐ OR ☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Robert P. Raymond	25,089	Susan K. Pocchiar	45,016
Alan R. Stempel	28,991	Philip I. Datlow	41,482
Mary-Ellen M. Devlin	27,928	Timothy X. Witkowski	40,232
Anthony P. Bottino	41,629	David A. Dow	46,124

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☒ Customer Number or Bar Code Label ☐ OR ☐ Correspondence address below

Name	28505		
Address	PATENT TRADEMARK OFFICE		
Address	28505		
City	State	ZIP	
Country	Telephone	Fax	

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Uwe		RIES	
Inventor's Signature	<i>Uwe Ries</i>	Date	06/04/2002
Residence: City	Biberach	State	Germany
Post Office Address	Tannenstrasse 31		
Post Office Address			
City	Biberach	State	Germany
ZIP	88400	Country	Germany
<input type="checkbox"/> Additional inventors are being named on the supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto			

Please type a plus sign (+) inside this box ☐

PTO/SB/02A (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION**ADDITIONAL INVENTOR(S)**

Supplemental Sheet

Page 1 of 2

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Henning		PRIERKE	
Inventor's Signature <i>H. Prierke</i>		Date 6/5/2002	
Residence: City Warthausen	State	Country DEX Germany	Citizenship DE
Mailing Address Birkenharder Strasse 11			
Mailing Address			
City Warthausen	State	ZIP 88447	Country Germany
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Armin		HECKEL	
Inventor's Signature <i>Armin Heckel</i>		Date 06/25/2002	
Residence: City Biberach	State	Country DEX Germany	Citizenship DE
Mailing Address Geschwister-Scholl-Strasse 71			
Mailing Address			
City Biberach	State	ZIP 88400	Country Germany
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Herbert		NAR	
Inventor's Signature <i>Herbert Nar</i>		Date 06/11/2002	
Residence: City Ochsenhausen	State	Country DEX Germany	Citizenship DE
Mailing Address Hexenweg 19			
Mailing Address			
City Ochsenhausen	State	ZIP 88416	Country Germany

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Case No. 5/1266

Please type a plus sign (+) inside this box → ☐PTO/SB/02A (11-00)
Approved for use through 10/31/2002 OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION**ADDITIONAL INVENTOR(S)**
Supplemental Sheet
Page 2 of 2

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Wolfgang		WIENEN	
Inventor's Signature <i>Wolfgang Wiener</i>		Date 06/14/02	
Residence: City Biberach	State	Country DE	Citizenship DE
Mailing Address Kirschenweg 27			
Mailing Address			
City Biberach	State	ZIP 88400	Country Germany
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Jean Marie		STASSEN	
Inventor's Signature <i>Jean Marie Stassen</i>		Date 07/17/02	
Residence: City LUBBEK	State	Country Belgium	Citizenship BE
Mailing Address Merellaan 31			
Mailing Address			
City LUBBEK	State	ZIP 3210	Country Belgium
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor	
Given Name (first and middle (if any))		Family Name or Surname	
Inventor's Signature		Date	
Residence: City	State	Country	Citizenship
Mailing Address			
Mailing Address			
City	State	ZIP	Country

Burden Hour Statement: This form is estimated to take 21 minutes to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Case No. 5/1266